As filed with the Securities and Exchange Commission on February 11, 2004
Registration No. 333-112012
--------------------------------------------------------------------------------
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
----------------------------------------
AMENDMENT NO. 1
TO
FORM S-3
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
----------------------------------------
Ionics, Incorporated
(Exact name of Registrant as specified in its charter)
-----------------------------
Massachusetts 04-2068530
(State or other jurisdiction (I.R.S. Employer
of incorporation or organization) Identification Number)
65 Grove Street
Watertown, MA 02472-2882
(617) 926-2500
(Address, including zip code, and telephone number,
including area code, of Registrant's principal executive offices)
----------------------------------------
Douglas R. Brown
President and Chief Executive Officer
Ionics, Incorporated
65 Grove Street
Watertown, MA 02472-2882
(617) 926-2500
(Name, address, including zip code, and telephone number,
including area code, of agent for service)
----------------------------------------
Copies of all communications, including all communications sent
to the agent for service, should be sent to:
Stephen Korn, Esq. Mark H. Burnett, Esq.
Vice President and General Counsel Testa, Hurwitz & Thibeault, LLP
Ionics, Incorporated 125 High Street
65 Grove Street Boston, Massachusetts 02110
Watertown, MA 02472-2882 (617) 248-7000
(617) 673-4450
Approximate date of commencement of proposed sale to the public: From time to
time after this Registration Statement becomes effective. If the only
securities being registered on this form are being offered pursuant to
dividend or interest reinvestment plans, please check the following box.
If any of the securities being registered on this Form are to be offered on
a delayed or continuous basis pursuant to Rule 415 under the Securities Act of
1933, other than securities offered only in connection with dividend or interest
reinvestment plans, check the following box. X
---
If this Form is filed to register additional securities for an offering
pursuant to Rule 462(b) under the Securities Act, please check the following box
and list the Securities Act registration statement number of the earlier
effective registration statement for the same offering.
If this Form is a post-effective amendment filed pursuant to Rule 462(c)
under the Securities Act, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement
for the same offering.
If delivery of the prospectus is expected to be made pursuant to Rule 434,
please check the following.
CALCULATION OF REGISTRATION FEE
------------------------------------------------- --------------- ------------------------- -------------------------- -------------
Amount to be Proposed Maximum Proposed Maximum Amount of
Title of Shares to be Registered Registered(1) Offering Price Per Aggregate Offering Registration
Share(2) Price(2) Fee(2)(3)
------------------------------------------------- --------------- ------------------------- -------------------------- -------------
Common Stock, $1.00 par value per share (and 4,915,660 $27.73
associated common stock purchase rights) (2) $136,311,252 $17,270.64
------------------------------------------------- --------------- ------------------------- -------------------------- -------------
(1) Of the shares of Ionics common stock being registered hereunder 4,905,660
shares represent the maximum aggregate number of shares of Ionics common
stock issuable to the owners of Ecolochem Inc. and its affiliated companies
(the "Ecolochem Selling Stockholders") pursuant to the purchase agreement
dated as of November 18, 2003, by and among Ionics, Incorporated and such
owners. Pursuant to Rule 416 under the Securities Act of 1933, as amended,
this prospectus will also cover an indeterminable number of additional
shares of common stock that may be issued to prevent dilution resulting
from stock splits, stock dividends or similar transactions affecting the
shares to be offered by the such owners.
The remaining 10,000 shares of Ionics common stock being registered
hereunder represents the maximum aggregate number of shares of Ionics
common stock issuable to Ruthal Limited upon exercise of stock options
granted to Ruthal Limited pursuant to that certain Option Agreement dated
as of March 21, 1995 by and among Ionics, Incorporated and Ruthal Limited
relating to 5,000 shares of Ionics common stock and that certain Option
Agreement dated as of June 1, 1995 by and among Ionics, Incorporated
relating to 5,000 shares of Ionics common stock. Pursuant to Rule 416 under
the Securities Act of 1933, as amended, this prospectus will also cover an
indeterminable number of additional shares of common stock that may be
issued to prevent dilution resulting from stock splits, stock dividends or
similar transactions affecting the shares to be offered by Ruthal Limited.
(2) Estimated solely for the purpose of calculating the registration fee
pursuant to Rule 457 under the Securities Act of 1933. Pursuant to Rule
457(c) under the Securities Act of 1933, the registration fee has been
calculated based upon the average of the high and low prices per share of
the common stock of Ionics, Incorporated on the New York Stock Exchange on
February 5, 2004. The common stock purchase rights that accompany the
common stock are issued without further consideration.
(3) The amount of $11,953.62 was paid by Ionics on January 20, 2004 when this
Registration Statement was first filed in respect of the registration of
4,905,660 shares of Ionics Common Stock. An additional 10,000 shares are
being registered pursuant to this Amendment No. 1. As such, Ionics is
paying an additional registration fee equal to $35.13. The $17,270.64
amount would only be payable by Ionics if it were registering all of the
4,915,660 shares as of the date hereof as it reflects the increase in the
Commission's filing fees effective after 10:00 p.m. on January 27, 2004.
This increase was not applicable to the shares originally registered on
January 20, 2004.
The Registrant hereby amends this registration statement on such date or
dates as may be necessary to delay its effective date until the Registrant shall
file a further amendment which specifically states that this registration
statement shall thereafter become effective in accordance with Section 8(a) of
the Securities Act of 1933 or until the registration statement shall become
effective on such date as the Commission, acting pursuant to Section 8(a), may
determine.
================================================================================
EXPLANATORY STATEMENT
Ionics, Incorporated and the owners (the "Ecolochem Selling
Stockholders") of the outstanding equity interests of Ecolochem, Inc., Ecolochem
International, Inc., Moson Holdings, LLC, and Ecolochem S.A.R.L. (collectively,
the "Ecolochem Group") have entered into the Purchase Agreement (referred to in
this registration statement as the "purchase agreement") dated as of November
18, 2003, pursuant to which Ionics will acquire the Ecolochem Group.
Of the 4,915,660 shares registered for resale pursuant to this
registration statement and the prospectus included in this registration
statement, 4,905,660 shares represent the maximum aggregate number of shares of
Ionics common stock to be issued in connection with the acquisition.
Certain statements in the prospectus included in this registration
statement assume completion of the acquisition of the Ecolochem Group by Ionics.
There can be no assurance, however, that the acquisition will be completed, or
if it is completed, when the closing of the acquisition will occur.
Subject to completion, dated February 11, 2004.
THE INFORMATION IN THIS PROSPECTUS IS NOT COMPLETE AND MAY BE CHANGED. THE
SECURITIES REGISTERED HEREUNDER MAY NOT BE SOLD UNTIL THE REGISTRATION STATEMENT
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION IS EFFECTIVE. THIS PROSPECTUS
IS NOT AN OFFER TO SELL SECURITIES, AND IT IS NOT SOLICITING OFFERS TO BUY THESE
SECURITIES IN ANY STATE WHERE THE OFFER OR SALE IS NOT PERMITTED.
PROSPECTUS
IONICS, INCORPORATED
4,915,660 Shares
Common Stock
This prospectus relates to 4,915,660 shares of our common stock held by
the selling stockholders. We will not receive any proceeds from the sale of
these shares by the selling stockholders. We have agreed to bear substantially
all of the expenses in connection with the registration and resale of the shares
(other than selling commissions and fees).
The Ecolochem Selling Stockholders include Lyman B. Dickerson; Douglas
G. Dickerson; The Estate of Richard C. Dickerson; The Lyman B. Dickerson
Revocable Trust Dated September 9, 1996 or any Successor Trustee, as amended;
The Richard Dickerson Revocable Trust Dated March 5, 1993, or any Successor
Trustee, as amended; The Douglas G. Dickerson Revocable Trust Dated June 22,
1988, or any Successor Trustee, as amended; The Lyman Dickerson Irrevocable
Trust, dated July 1, 1991; The Richard Dickerson Irrevocable Trust No. 3, dated
July 1, 1991; and The Douglas Dickerson Irrevocable Trust No. 3, dated July 1,
1991 and certain of their permitted transferees. The Ecolochem Selling
Stockholders will acquire the offered shares directly from Ionics upon the
consummation of Ionics' acquisition of Ecolochem, Inc. and its affiliated
companies.
Ruthal Limited is also included as a selling stockholder hereunder.
Ruthal Limited has the right to acquire the shares of our common stock to be
offered hereunder upon the exercise of outstanding options to purchase an
aggregate of 10,000 shares of our common stock. We have agreed to include the
shares of our common stock to be offered hereunder by Ruthal Limited pursuant to
certain contractual registration rights we previously granted to Ruthal Limited.
As used herein, the term "selling stockholders" includes the Ecolochem
Selling Stockholders, Ruthal Limited and the permitted transferees or other
successors-in-interest of the Ecolochem Selling Stockholders and Ruthal Limited.
The selling stockholders may offer the shares from time to time through public
or private transactions at prevailing market prices, at prices related to
prevailing market prices or at privately negotiated prices.
Our common stock is traded on the New York Stock Exchange under the
symbol "ION." On February 6, 2004, the closing sale price of our common stock on
the New York Stock Exchange was $28.40 per share.
------------------------
Investing in our common stock involves risk.
See "Risk Factors" beginning on page 1.
------------------------
Neither the Securities and Exchange Commission nor any state securities
commission has approved or disapproved of these securities, or determined if
this prospectus is truthful or complete. Any representation to the contrary is a
criminal offense.
Prospective investors should rely only on the information contained in
this prospectus or information specifically incorporated by reference in this
prospectus. We have not authorized anyone to provide prospective investors with
information that is different.
Neither the delivery of this prospectus, nor any sale of the shares,
shall create any implication that the information in this prospectus is correct
after the date hereof.
The date of this prospectus is ________ __, 2004.
------------------------
TABLE OF CONTENTS
Page
Ionics, Incorporated......................................................... 1
Risk Factors................................................................. 1
Special Note Regarding Forward-Looking Information........................... 10
Use of Proceeds.............................................................. 11
Selling Stockholders......................................................... 11
Plan of Distribution......................................................... 13
Legal Matters................................................................ 15
Experts...................................................................... 15
Where You Can Find More Information.......................................... 16
Incorporation of Certain Documents by Reference.............................. 16
------------------------
IONICS, INCORPORATED
We are a leading water purification company engaged worldwide in the
supply of water and related activities and the supply of water treatment
equipment through the use of proprietary separations technologies and systems.
Our products and services are used by us or our customers to desalt brackish
water and seawater, recycle and reclaim process water and wastewater, treat
water in the home, manufacture and supply water treatment chemicals and
ultrapure water, process food products and recycle and measure levels of
waterborne contaminants and pollutants. Our customers include industrial
companies, consumers, municipalities and other governmental entities, and
utilities.
Ionics was incorporated in Massachusetts in 1948. Our principal
executive offices are located at 65 Grove Street, Watertown, Massachusetts 02472
and our telephone number is (617) 926-2500.
RISK FACTORS
You should carefully consider the risks described below before you decide
to buy our common stock. The risks and uncertainties described below are not the
only ones facing our company. Additional risks and uncertainties may also impair
our business operations. In evaluating our business and before you decide to buy
our common stock, you should consider carefully the following risks, in addition
to the other information contained in this prospectus and the other documents
incorporated by reference into this prospectus. If any of the following risks
actually occur, our business, financial condition or results of operations would
likely suffer. In such case, the trading price of our common stock could
decline, and you may lose all or part of the money you paid to buy our common
stock.
Our results of operations may fluctuate significantly on a quarterly basis.
Our quarterly operating results may vary significantly from quarter to
quarter, depending on a number of factors including:
o the introduction and market acceptance of new products and new variations of
existing products;
o the activities of competitors;
o our ability to control expenses;
o variations in the timing of orders and subsequent shipments;
o length of approval processes or market tests;
o changes in our mix of products;
o disruption in our sources of supply;
o personnel changes;
o changes in our capital spending;
o unforeseeable or unavoidable delays in large-scale customer projects;
o higher interest rates; and
o general economic conditions.
The market value of the shares of our common stock issuable in connection with
the acquisition of the Ecolochem Group may increase prior to the closing of the
acquisition and, therefore, we may be perceived to have paid more for the
Ecolochem Group.
The number of shares of our common stock issuable pursuant to the
acquisition was fixed at the time of the signing of the purchase agreement with
the owners of the Ecolochem Group and is not subject to adjustment based on
changes in the trading price of our common stock before the closing of the
acquisition. Therefore, the market value of the shares of our common stock
issued in connection with the acquisition will likely fluctuate through the
closing of the acquisition and thereafter. As a result, the value of the
acquisition, as reflected in the relative market price of our common stock, may
vary significantly from the date of execution of the purchase agreement and the
date the acquisition is completed. This variance may arise due to, among other
things: changes in our business, operations and prospects; market assessments of
the likelihood that the acquisition will be completed; demand for water
processing in our markets; and interest rates, general market and economic
conditions and other factors. Substantially all of these factors are beyond our
control. As a result of increases in the market price of our common stock,
financial or industry analysts or others may perceive that we paid more for the
Ecolochem Group than they believe was prudent. If this perception materializes,
the trading price of our common stock could be adversely affected.
The anticipated benefits of acquiring Ecolochem, Inc. and its affiliated
companies (the "Ecolochem Group") may not be realized.
We agreed to acquire the Ecolochem Group with the expectation that the
acquisition would result in various benefits including, among other things,
enhanced revenue, profits, market presence, cost savings and operating
efficiencies. We expect that the acquisition will enhance our position in the
water treatment services market through the combination of our technologies,
products, services and customer contacts with those of the Ecolochem Group, and
will enable us to broaden our customer base in the electric power and
petrochemical industries. If our business or the Ecolochem Group's business
fails to meet the demands of the marketplace, customer acceptance of our
products and services could decline, which would have an adverse effect on our
results of operations and financial condition. We may not realize any of these
benefits and the acquisition may result in the deterioration or loss of
significant business. Costs incurred and potential liabilities assumed in
connection with the acquisition, including pending and threatened disputes,
litigation and environmental liabilities, could have a material adverse effect
on our business, financial condition and operating results.
In addition, we may not achieve the anticipated benefits as rapidly as,
or to the extent, anticipated by certain financial or industry analysts, or
other analysts may not perceive the same benefits to the acquisition as we do.
If these risks materialize, our stock price could be adversely affected.
Our restructuring program may not result in the intended financial performance
improvements.
On September 3, 2003, we announced a restructuring program intended to
improve our financial performance through a realignment of our management
structure, a reduction in personnel, and the consolidation of certain
operations. The program when fully carried out would result in the elimination
of approximately 200 positions, or approximately 10% of our workforce, and is
anticipated to result in annual personnel savings of approximately $14 million
and annual facilities savings of approximately $1.4 million. In connection with
the restructuring program, we anticipate incurring charges for severance costs,
facilities shutdown and relocation costs, and reporting process improvement
costs totaling approximately $11 million, as well as goodwill impairment and
other long-lived asset impairment charges.
A number of the planned restructuring actions have been taken, and
others have yet to be implemented. We may not be able to complete the
implementation of the restructuring program to the extent and according to the
timetable presently expected. The cost savings we realize from the restructuring
may be less than anticipated, and the overall restructuring costs we incur may
be greater than anticipated. Consequently, the overall impact of the
restructuring on our profitability may differ from our original estimate.
We may have difficulty and incur substantial costs integrating the Ecolochem
Group.
- 2 -
Integrating the Ecolochem Group will be a complex, time-consuming and
expensive process. Before the acquisition of Ecolochem Group, Ionics and the
Ecolochem Group operated independently, each with its own business, products,
customers, employees, culture and systems, including data management and
financial systems. Additionally, we are currently in the process of
restructuring our business and operations. We may face substantial difficulties,
costs and delays in integrating the Ecolochem Group, which may include:
o perceived adverse changes in product or service offerings or customer service
standards, whether or not these changes do, in fact, occur;
o costs and delays in implementing common information and other systems
and procedures and costs and delays caused by communication difficulties;
o potential difficulty in applying our accounting controls and procedures to
the members of the Ecolochem Group, which have operated as independent
private companies;
o charges to earnings resulting from the application of purchase accounting to
the acquisition;
o diversion of management resources;
o potential incompatibility of business cultures;
o potential losses of management and other key employees due to perceived
uncertainty in career opportunities, compensation levels and benefits;
o the retention of existing customers of each company;
o reduction or loss of customer orders due to the potential for market
confusion, hesitation and delay; and
o coordinating infrastructure operations in a rapid and efficient manner.
After the acquisition, we will seek to combine certain operations and
functions using common information and communication systems, operating
procedures, financial controls and human resource practices, including training,
professional development and benefit programs. We may be unsuccessful, or
experience delays, in implementing the integration of these systems and
processes.
Any one or all of these factors may cause increased operating costs,
worse than anticipated financial performance or the loss of customers and
employees. Many of these factors are outside our control. The failure to timely
and efficiently integrate the Ecolochem Group could have a material adverse
effect on our business, financial condition and operating results. In addition,
the differences between the business cultures could present significant
obstacles to timely, cost-effective integration of the Ecolochem Group.
We may have difficulty establishing appropriate controls and procedures on a
timely basis with respect to the Ecolochem Group's financial reporting as our
subsidiaries.
We have been implementing a number of measures and procedures to ensure
that our disclosure controls and procedures and internal controls over financial
reporting are effective. The acquisition of the Ecolochem Group will add
significant business units to our operations, which, prior to the acquisition,
were operated as private businesses and were not subject to the various
reporting obligations imposed on publicly traded companies. We will be required
to establish appropriate controls and procedures in accordance with our policies
and procedures with respect to the Ecolochem Group's financial reporting.
Failure to establish those controls and procedures in a timely manner, or any
failure of those controls and procedures once established, could adversely
impact our public disclosures regarding our business, financial condition or
operating results, which may adversely impact the price of our common stock.
The debt we will incur in connection with the acquisition of the Ecolochem Group
will create financial and operating risks that could limit our operating
flexibility and growth.
- 3 -
As a result of the acquisition of the Ecolochem Group, we will incur
substantial additional debt. We expect that the terms of the new credit
facilities will contain provisions that limit our ability to incur additional
indebtedness in the future and place other restrictions on our business. We may
not be able to repay any current or future debt on a timely basis, depending on
our future operating results. We will be required to devote increased amounts of
our cash flow to service indebtedness incurred in connection with the
acquisition or incurred in the future. This could require us to modify, delay or
abandon our capital expenditures and other investments necessary to implement
our business plan.
A portion of this debt, as well as other short-term and long-term
borrowings, will be subject to variable interest rates tied to prime rates or
other indices. We will be subject to the risk that interest rates may increase
significantly and increase the cost of our debt.
The success of our strategic plan to grow sales and develop relationships
internationally may be limited by risks related to conducting business in
international markets.
Although both Ionics and the Ecolochem Group have experience marketing and
distributing their products and services and developing strategic relations in
Europe and other foreign markets, part of our strategy will be to increase sales
and build additional relationships in Europe and other foreign markets. Risks
inherent in marketing, selling and developing relationships in European and
other foreign markets include those associated with:
o Economic conditions in those markets, including fluctuations in the
relative values of the U.S. dollar and foreign currencies;
o Taxes and fees imposed by foreign governments that may increase the cost of
products and services; and
o Laws and regulations imposed by individual countries and by the European Union
and other governmental bodies.
We have only limited protection for our proprietary technology.
We rely on a combination of patent, trademark and trade secret laws and
restrictions on disclosure to protect our intellectual property rights. Our
success depends in part on our ability to obtain new patents and licenses and to
preserve other intellectual property rights covering our products. We intend to
continue to seek patents on our inventions when appropriate. The process of
seeking patent protection can be time consuming and expensive and we cannot
assure you that any new patent applications will be approved, that any patents
that may issue will protect our intellectual property or that any issued patents
will not be challenged by third parties or will be sufficient in scope or
strength to provide meaningful protection or any commercial advantage to us.
Other parties may independently develop similar or competing technology or
design around any patents that may be issued to us. We cannot be certain that
the steps we have taken will prevent the misappropriation of our intellectual
property, particularly in foreign countries where the laws may not protect our
proprietary rights as fully as in the United States.
We may become subject to infringement claims.
Although we do not believe that our products infringe the proprietary
rights of any third parties, we have in the past been subject to infringement
claims and third parties might assert infringement claims against us or our
customers in the future. Furthermore, we may initiate claims or litigation
against third parties for infringement of our proprietary rights or to establish
the validity of our proprietary rights. Litigation, either as plaintiff or
defendant, would cause us to incur substantial costs and divert management
resources from productive tasks. Any litigation, regardless of the outcome,
could harm our business.
- 4 -
If it appears necessary or desirable, we may seek licenses to
intellectual property that we are allegedly infringing. We may not be able to
obtain licenses on acceptable terms. The failure to obtain necessary licenses or
other rights could harm our business.
We have many competitors and we may not be able to compete effectively.
We experience competition from a variety of sources with respect to
virtually all of our products, although we do not know of any single entity that
competes with us across the full range of our products, systems and services.
Competition in the markets that we serve is based on a number of factors,
including price, technology, applications experience, know-how, availability of
financing, reputation, product warranties, reliability, service and
distribution. Many of our current and potential competitors have greater name
recognition and substantially greater financial, marketing and other resources
than we do. These greater resources could, for example, allow our competitors to
develop technology, products and services superior to our own. As a result, we
may not be able to compete effectively with current or future competitors.
We may not be able to develop the new products or acquire the rights to new
products necessary to remain competitive.
The water purification industry is characterized by ongoing
technological developments and changing customer requirements. As a result, our
success and continued growth depend, in part, on our ability to develop or
acquire rights to and successfully introduce into the marketplace enhancements
of existing products or new products that incorporate technological advances,
meet customer requirements and respond to products developed by our competition.
There can be no assurance that we will be successful in developing or acquiring
such rights to products on a timely basis or that such products will adequately
address the changing needs of the marketplace.
We may not be able to adapt to changes in technology and government regulation
fast enough to remain competitive.
The water purification industry is characterized by changing
technology, competitively imposed process standards and regulatory requirements,
each of which influences the demand for our products and services. Changes in
legislative, regulatory or industrial requirements may render certain of our
purification products and processes obsolete. Acceptance of new products may
also be affected by the adoption of new government regulations requiring
stricter standards. Our ability to anticipate changes in technology and
regulatory standards and to develop and introduce new and enhanced products
successfully on a timely basis will be a significant factor in our ability to
grow and to remain competitive. There can be no assurance that we will be able
to achieve the technological advances that may be necessary for us to remain
competitive or that certain of our products will not become obsolete. In
addition, we are subject to the risks generally associated with new product
introductions and applications, including lack of market acceptance, delays in
development, or failure of products to operate properly.
A portion of our sales is dependent upon our customers' spending cycles for
capital equipment.
The sale of capital equipment within the water purification industry is
cyclical and influenced by various economic factors including interest rates and
general fluctuations of the business cycle. Our Equipment Business Group and our
Ultrapure Water Group each derive a significant portion of its revenue from the
sale of capital equipment. While we sell capital equipment to customers in
diverse industries and in domestic and international markets, cyclicality of
capital equipment sales and general economic conditions could have an adverse
effect on our revenues and profitability.
- 5 -
The acquisition of the Ecolochem Group may result in a loss of customers,
strategic partners and suppliers.
The acquisition of the Ecolochem Group may have the effect of
disrupting customer relationships. Some of our customers or potential customers
and those of the Ecolochem Group may delay or alter buying patterns as they
evaluate the likelihood of successful integration of the Ecolochem Group's
business following the acquisition. Other customers may seek alternative sources
of products or services due to, among other reasons, a desire not to do business
with us or perceived concerns that we may not continue to support certain
products or services. In addition, by increasing the breadth of our business,
the acquisition may make it more difficult for us to enter into relationships
with customers and strategic partners, some of whom may view us as a more direct
competitor than we were prior to the acquisition. Therefore, we could experience
some customer attrition as a result of the acquisition.
In addition, certain customers of the Ecolochem Group have the right to
terminate their agreements with the Ecolochem Group as a result of the
acquisition. Some or all of those customers may exercise that right, resulting
in the loss of related revenue and profits. The indemnification obligations of
the owners of the Ecolochem Group with respect to any such terminations may not
fully compensate us for the loss of those customers or the related revenue and
profit.
Difficulties in integrating operations could also result in the loss of
strategic partners and suppliers and potential disputes or litigation with
customers, strategic partners, suppliers, resellers or others. There can be no
assurance that any steps by management to counter such potential increased
customer, strategic partner or supplier attrition will be effective.
Failure by management to control customer, strategic partner and
supplier attrition could have a material adverse effect on our business,
financial condition and operating results.
The results of operations of the Ecolochem Group tend to fluctuate because of
the weather conditions that affect its customers.
Demand for the mobile water treatment services offered by the Ecolochem
Group tends to increase during periods of severe hot or cold weather resulting
in increased revenues and earnings. The absence of severe weather may adversely
impact the revenue and operating results of the Ecolochem Group.
We must comply with significant environmental regulations, which can be
difficult and expensive.
We are subject to a variety of federal, state and local governmental
regulations related to the use, storage, discharge and disposal of toxic,
volatile or otherwise hazardous chemicals used in our manufacturing processes.
Although we believe that our activities conform to presently applicable
environmental regulations, the failure to comply with present or future
regulations could result in fines being imposed on us, suspension of production
or a cessation of operations. Any failure by us to control the use of, or
adequately restrict the discharge of, hazardous substances, or otherwise comply
with environmental regulations, could subject us to significant future
liabilities. In addition, we cannot assure you that past use or disposal of
environmentally sensitive materials in conformity with then existing
environmental laws and regulations will not result in remediation or other
significant liabilities under current or future environmental laws or
regulations.
We depend on key personnel, the loss of whom could harm our business.
We have been and are presently dependent upon the continued efforts of
our senior management team, including Douglas R. Brown, our President and Chief
- 6 -
Executive Officer. The loss of the services of Mr. Brown or any other members of
our senior management team could have a material adverse effect on our ability
to achieve our objectives. We will enter into an employment agreement with Mr.
Lyman Dickerson, the President of Ecolochem, Inc., with the intent of providing
Mr. Dickerson with sufficient incentive to remain employed by us. However, it
cannot be assured that he will remain employed with us.
The loss of our key personnel, including those of the Ecolochem Group,
could adversely affect our ability to manage our business. We believe that the
continued service of our executive officers and the executive officers of the
Ecolochem Group will be important to our future growth and competitiveness. Our
employees and those of the Ecolochem Group are entitled to voluntarily terminate
their relationship with us or with the Ecolochem Group, typically without any,
or with only minimal, advance notice. The process of finding additional trained
personnel to carry out our strategy could be lengthy, costly and disruptive. We
might not be able to retain the services of all of our or the Ecolochem Group's
key employees or a sufficient number of them to execute our plans. In addition,
we might not be able to continue to attract new employees as required.
The loss of the services of any member of our or the Ecolochem Group's
management team, or of any other key employee, could divert management's time
and attention, increase our expenses and adversely affect our ability to conduct
our business efficiently.
If we are unable to continue to hire and retain skilled technical and scientific
personnel, then we will have trouble developing products.
Our success depends largely upon the continued service of our
management and scientific staff and our ability to attract, retain and motivate
highly skilled scientific, management and marketing personnel. We face
significant competition for such personnel from other companies, research and
academic institutions, government and other organizations who may better be able
to attract such personnel. The loss of key personnel or our inability to hire
and retain personnel who have technical and scientific backgrounds could
materially adversely affect our product development efforts and our business.
If certain intangible assets acquired in the acquisition of the Ecolochem Group
subsequently become impaired, we may be required to write off, or reduce the
value of, those intangible assets, which would adversely impact our financial
results during the periods in which they occur.
We currently expect to record approximately $183.8 million of goodwill
and $73 million of other intangible assets in connection with the acquisition of
the Ecolochem Group. Goodwill associated with the acquisition will be required
to be tested at least annually for impairment. Other intangible assets will be
amortized over their estimated useful lives. If the goodwill or other intangible
assets are deemed to be impaired in the future, we will be required to reduce
the value of those assets or to write them off completely, which would reduce
our reported financial results during the periods in which such determination is
made. If we are required to write down or write off all or a portion of those
assets, or if financial analysts or investors believe we may be required to take
such action in the future, the prices at which our common stock trades may be
adversely affected.
We may not derive any income tax benefits from the tax election which we
currently intend to make.
We may elect to make, with the former shareholders of Ecolochem, Inc.
and Ecolochem International, Inc., an election under Section 338(h)(10) of the
Internal Revenue Code of 1986, as amended (the "Code"), with respect to the
acquisition of Ecolochem, Inc., Ecolochem International, Inc. or both. If a
valid election is made under Section 338(h)(10) of the Code, we will generally
be able to treat the acquisition of the stock of any company with respect to
which such election is made as if new subsidiaries of ours had acquired the
assets of such company in a taxable transaction for federal income tax purposes,
and, as a result, after the acquisition, the assets of such company will have a
- 7 -
tax basis generally equal to the cash and other property paid by us for such
company plus any liabilities of such company that are assumed in the
transaction.
The principal tax advantage of making an election under Section
338(h)(10) of the Code is that our new subsidiary or subsidiaries, as the case
may be, will be able to depreciate or amortize the new federal income tax basis
of depreciable or amortizable assets over time periods specified in the Code.
For intangible assets, that time period is generally 15 years.
We may not be eligible to make an election under Section 338(h)(10) of
the Code with respect to Ecolochem, Inc., Ecolochem International, Inc. or both.
Currently, we intend to make an election under Section 338(h)(10) of the Code
only with respect to Ecolochem, Inc., but we may conclude to make an election
under Section 338(h)(10) of the Code with respect to Ecolochem International,
Inc. as well. Furthermore, even if a valid election under Section 338(h)(10) of
the Code is made, the depreciation and amortization deductions with respect to
certain assets acquired from the Ecolochem Group may not be available to us. As
a result, your decision to buy our common stock should not be based on any tax
benefits associated with such an election or on any other tax benefits
associated with the acquisition.
If we make an election under Section 338(h)(10) of the Code, we will be
required to pay additional amounts to certain of the former owners of the
Ecolochem Group. These amounts will be significant.
Following the closing of the acquisition of the Ecolochem Group, we will be
subject to significant influence by the former owners of the Ecolochem Group.
Following the closing of the acquisition, the former owners of the
Ecolochem Group will beneficially own approximately 20% of our common stock. As
a result, they have a strong influence on matters requiring approval by our
stockholders, such as the election of directors and most corporate actions,
including mergers and acquisitions. In addition, the former owners of the
Ecolochem Group will be entitled to designate two members of our Board of
Directors. These directors will have the opportunity to participate in all
matters brought before the Board of Directors. Moreover, Mr. Lyman Dickerson,
the President of Ecolochem, Inc., will have the opportunity to become the
Chairman of our Board of Directors pursuant to the terms of the Stockholders
Agreement to be entered into in connection with the acquisition of the Ecolochem
Group. Collectively, these arrangements will allow the former owners of the
Ecolochem Group to have significant participation in matters affecting us.
Future sales of our common stock by the former owners of the Ecolochem Group
could depress the market price of our common stock.
While the former owners of the Ecolochem Group will be subject to
restrictions on their ability to resell a portion of the shares of common stock
issued to them in connection with our acquisition of the Ecolochem Group during
the six months following the closing of the acquisition, they will be entitled
to dispose of a significant number of shares in the public market, which could
cause the market price of our common stock to decrease significantly. All of the
former owners of the Ecolochem Group are required to enter into an agreement
under which they agree not to sell more than 10% of the shares of common stock
issuable to them in the acquisition for a period of six months following the
closing of the acquisition, subject to certain exceptions. Such restrictions
will lapse six months after the closing of the acquisition and the former owners
of the Ecolochem Group will then have no limitations on the number of shares
they can sell in the public market. If such persons sell a significant number of
shares of the common stock in the open market, our stock price could decline.
Substantial expenses will be incurred and payments made even if the acquisition
of the Ecolochem Group is not completed.
- 8 -
The acquisition may not be completed. Whether or not the acquisition is
completed, we will incur substantial expenses in pursuing the acquisition,
including:
o Financial advisory fees (certain of which are conditioned upon the
consummation of the acquisition) and expenses;
o Fees and expenses incurred in connection with the proposed financing of the
acquisition; and
o Costs and expenses for services provided by our lawyers, accountants and other
advisors.
If the acquisition is completed, the transaction costs and expenses
attributable to advisory, legal and accounting services incurred by us will be
capitalized as a component of the purchase price.
We expect to charge certain other transaction costs and expenses during
the periods in which they are incurred, which will reduce earnings or increase
losses during those periods. We might not be able to manage these
acquisition-related costs effectively, and they could be higher than are
currently estimated. If these costs are not managed effectively, our business
operations, financial results and stock price could be adversely affected.
The costs and expenses we incur in connection with the acquisition,
other than certain fees payable to our financial advisor, must be paid even if
the acquisition is not completed. If the acquisition is not completed, these
expenses will reduce earnings or increase losses during the period in which it
is determined the acquisition will not be completed. In addition, under certain
circumstances if the acquisition is not completed, we may be required to pay a
termination fee of up to $13.2 million or in other instances to pay the
reasonable costs and expenses of the owners of the Ecolochem Group of up to a
maximum of $4.5 million.
Failure to complete the acquisition could cause our stock price to decline.
If the acquisition is not completed for any reason, our stock price may
decline to the extent that the current market price reflects a market assumption
that the acquisition will be completed or the market's perceptions why the
acquisition was not consummated. In addition, our stock price may decline
because costs related to the acquisition, such as legal, accounting and certain
financial advisor fees, must be paid even if the acquisition is not completed,
adversely affecting our earnings during the period for which such costs are
recognized.
Failure of any of the members of the Ecolochem Group to be a "pass-through"
entity for United States federal and other tax purposes could increase our cost
of the cost of the acquisition.
The owners of the Ecolochem Group have represented in the purchase
agreement that each of the members of the Ecolochem Group is a "pass-through"
entity for United States federal income tax purposes. Specifically, the owners
of the Ecolochem Group have represented that each of Ecolochem and Ecolochem
International, Inc. is a "Subchapter S Corporation" under the Code, and that
each of Moson Holdings, LLC and Ecolochem S.A.R.L. is treated as a "partnership"
under the Code for federal tax purposes. Accordingly, except in limited
circumstances, the Ecolochem Group does not, and has not for a substantial
period, paid income taxes at the entity level either to the United States or to
many state and local jurisdictions (with certain exceptions). If it were
ultimately determined that any member of the Ecolochem Group was not a valid
pass-through entity for tax purposes, that entity could be subject to tax,
penalties, additions to tax and interest for prior periods. The owners of the
Ecolochem Group are required to indemnify us for any taxes attributable to
periods prior to the acquisition, but there can be no assurance that any such
- 9 -
amount will actually be paid. Any significant tax, penalties, additions to tax
and interest for prior periods which we pay and for which we are not indemnified
by the owners of the Ecolochem Group could have a material adverse effect on our
business, financial condition and operating results.
SPECIAL NOTE REGARDING FORWARD-LOOKING INFORMATION
Certain statements and assumptions contained, or incorporated by
reference, in this prospectus constitute forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended. These statements include
those that predict, forecast, indicate or imply future results, performance or
achievements.
Any statements contained in this prospectus, including statements to
the effect that Ionics or its management "believes," "expects," "anticipates,"
"plans," "may," "will," "projects," "continues," or "estimates" or statements
concerning "potential" or "opportunity" or other variations thereof or
comparable terminology or the negative thereof, that are not statements of
historical fact should be considered forward-looking statements.
These forward-looking statements are based on current views and
assumptions and are neither promises nor guarantees but are subject to risks,
uncertainties and other factors that could cause actual results to differ
materially from current expectations as described in such forward-looking
statements. In connection with the forward-looking statements appearing in this
prospectus, you should carefully consider the matters discussed under the
caption "Risk Factors" beginning on page 1, and the other risk factors described
in Ionics' filings with the SEC, including its Proxy Statement dated January 9,
2004 and its Annual Report on Form 10-K for the year ended December 31, 2002, as
amended. We do not assume any obligation to update any forward-looking statement
we make, except as required by law.
- 10 -
USE OF PROCEEDS
We will not receive any of the proceeds from the sale of our common
stock by the selling stockholders. The selling stockholders will receive all of
the net proceeds from any sale of the shares of common stock being sold by the
selling stockholders pursuant to this prospectus.
The selling stockholders will pay any underwriting discounts and
commissions, all transfer taxes, and all expenses incurred by the selling
stockholders for brokerage, accounting, tax or legal services (except that we
have agreed to pay the fees and disbursements of one law firm representing the
selling stockholders on behalf of the selling stockholders) or any other
expenses incurred by the selling stockholders in disposing of the shares. We
will bear all other costs, fees and expenses incurred in effecting the
registration of the shares covered by this prospectus, including, without
limitation, all registration and filing fees, New York Stock Exchange listing
fees and fees and expenses of our counsel, and fees and expenses of one counsel
to the Ecolochem Selling Stockholders and our accountants.
SELLING STOCKHOLDERS
The following table sets forth, to our knowledge, the name and number
of shares of our common stock beneficially owned by each of the selling
stockholders. With respect to the Ecolochem Selling Stockholders, the
information is provided as of the consummation of our acquisition of Ecolochem,
Inc. and its affiliated companies. With respect to Ruthal Limited, the
information is provided as of the date hereof. Beneficial ownership is
determined in accordance with the rules of the Securities and Exchange
Commission, and includes voting or investment power with respect to shares.
Unless otherwise indicated below, to our knowledge, all persons named in the
table have sole voting and investment power with respect to their shares of
common stock and except as set forth in the footnotes to the table. The
inclusion of any shares in this table does not constitute an admission of
beneficial ownership for the person or trust named below. The table has been
prepared on the basis of information furnished to us by or on behalf of the
selling stockholders. As of February 6, 2004, there were approximately
17,925,036 shares of our common stock outstanding.
Shares of Common Shares of Common Stock to
Stock Beneficially be Beneficially
Owned Prior to Owned After Offering(1)(3)
Offering(1)
Number of Shares
of Common Stock
Being Offered
Name of Selling Stockholder Pursuant to this
Prospectus(2)
Number Percent Number Percent
The Lyman B. Dickerson Revocable Trust dated 0 * 2,163,250 0 *
September 9, 1996 or any Successor Trustee,
as amended (4)
The Douglas G. Dickerson Revocable Trust 0 * 1,081,625 0 *
dated June 22, 1988 or any Successor
Trustee, as amended (5)
The Richard Dickerson Revocable Trust dated 0 * 1,081,625 0 *
March 5, 1993, or any Successor Trustee,
as amended (6)
The Lyman Dickerson Irrevocable Trust, dated 0 * 289,580 0 *
July 1, 1991 (7)
The Douglas Dickerson Irrevocable Trust No. 0 * 144,790 0 *
3, dated July 1, 1991 (8)
The Richard Dickerson Irrevocable Trust No. 0 * 144,790 0 *
3, dated July 1, 1991 (9)
Ruthal Limited(101) 38,900 * 10,000 30,400 *
---------------------
- 11 -
* Less than one percent.
(1) In connection with the consummation of our acquisition of the Ecolochem
Group each of the Ecolochem Selling Stockholders will agree not to
transfer, during the six months following the consummation of the
acquisition, more than 10% of the shares of our common stock issued to them
by us in connection with the acquisition other than transfers to certain
related persons. Each of the Ecolochem Selling Stockholders will also agree
to certain restrictions on the sale or other transfer of such shares of our
common stock to certain competitors of ours.
(2) Pursuant to Rule 416 under the Securities Act of 1933, as amended, this
prospectus will also cover an indeterminable number of additional shares of
common stock that may be issued to prevent dilution resulting from stock
splits, stock dividends or similar transactions affecting the shares to be
offered by the selling stockholders.
(3) Notwithstanding the foregoing, we do not know when or in what amounts a
selling stockholder may offer shares for sale. The selling stockholders may
sell any or all of the shares offered by this prospectus. Because the
selling stockholders. may offer all or some of the shares pursuant to this
offering, and because there are currently no agreements, arrangements or
understandings with respect to the sale of any of the shares, we cannot
estimate the number of the shares that will be held by the selling
stockholders after completion of the offering. However, for purposes of
this table, we have assumed that, after completion of the offering, none of
the shares covered by this prospectus will be held by the selling
stockholders.
(4) Lyman B. Dickerson, as sole trustee, holds sole voting and dispositive
power with respect to these shares. (5) Douglas G. Dickerson, as sole
trustee, holds sole voting and dispositive power with respect to these
shares. (6) Douglas G. Dickerson and Marguerite W. Dickerson, as
co-trustees, share voting and dispositive power with respect to these
shares.
(7) Lyman B. Dickerson, as trustee and Charles C. Kline, as independent trustee
share voting and dispositive power with respect to these shares.
(8) Douglas G. Dickerson, as trustee and Frederick T. Stant, III, as
independent trustee share voting and dispositive power with respect to
these shares.
(9) Douglas G. Dickerson and Marguerite W. Dickerson as co-trustees and
Frederick T. Stant, as independent trustee, share voting and dispositive
power with respect to these shares.
(10) As of the date of this prospectus, Ruthal Limited is the owner of 30,400
shares of our common stock. The shares of our common stock to be registered
for resale hereunder by Ruthal Limited may be obtained through Ruthal
Limited's exercise of outstanding options to purchase our common stock. On
March 21, 1995 we entered into an Option Agreement with Ruthal Limited that
permitted the exercise by Ruthal Limited of 500 shares of our common stock
on March 21, 1996 and an additional 500 shares on and after each succeeding
anniversary of such date. At present, 4,000 of such shares are fully
exercisable and 4,500 of such shares are deemed to be beneficially owned by
Ruthal Limited. On June 1, 1995 we entered into an Option Agreement with
Ruthal Limited that permitted the exercise by Ruthal Limited of 500 shares
of our common stock on March 21, 1996 and an additional 500 shares on and
after each succeeding anniversary of such date. At present, 4,000 of such
shares are fully exercisable.
Each of the Ecolochem Selling Stockholders is to receive the shares of
our common stock held by them in connection with the consummation of our
acquisition of Ecolochem, Inc. and its affiliated companies. We intend to
appoint Mr. Lyman Dickerson to our Board of Directors simultaneously with the
closing of the acquisition. Mr. Lyman Dickerson has substantial direct and
indirect interests in the acquisition. Each of the Ecolochem Selling
Stockholders may be considered associates of Mr. Lyman Dickerson under the rules
of the Securities Exchange Act of 1934, as amended. In addition, upon the
closing of the acquisition, we will enter into an employment agreement with Mr.
Lyman Dickerson. The terms of this agreement provide that Mr. Lyman Dickerson
will be employed as the Vice President of our Water Systems Division (which
includes, among other operations, the Ecolochem Group and its respective
subsidiaries and our Ultrapure Water and Industrial Water operations). In this
position, Mr. Lyman Dickerson will be the senior executive officer for the
- 12 -
Division and will be responsible for managing the integration of the Ecolochem
Group with our existing operations. The term of this agreement is for two years
unless sooner terminated for "cause" (as defined therein) or under certain other
circumstances. Under the terms of his employment agreement, Mr. Lyman Dickerson
will be entitled to, among other things: an initial base annual salary of
$250,000; participation in our executive bonus program and stock option plans
(as determined by our Board of Directors); participation in our benefit plans;
and a severance benefit should his employment agreement be terminated by us
prior to the expiration of its term for reasons other than "cause".
Each selling stockholder represented to us that he or it acquired the
shares of common stock for investment and not with a view to any public
distribution thereof in violation of any of the registration requirements of the
Securities Act of 1933, as amended. In addition, each selling stockholder has
represented that he or it qualifies as an "accredited investor" as such term is
defined in Rule 501 of Regulation D under the Securities Act of 1933, as
amended.
In recognition of the fact that the Ecolochem Selling Stockholders may
desire the ability to sell the shares when they consider it appropriate, in
connection with the acquisition we agreed to file with the Securities and
Exchange Commission a registration statement (of which this prospectus is a
part) to permit the resale of the shares from time to time and to use our
commercially reasonable efforts to keep the registration statement effective,
solely with respect to the shares held by the Ecolochem Selling Stockholders,
for the period from effectiveness of the registration statement of which this
prospectus forms a part until the first date on which (i) the Ecolochem Selling
Stockholders cease to hold in the aggregate a number of shares of common stock
equal to the lesser of (a) at least 5% of the number of outstanding shares of
our common stock as of the close of business on the day immediately preceding
the date upon which we consummate the acquisition of Ecolochem, Inc. and its
affiliated companies and (b) at least 5% of the number of outstanding shares of
our Common Stock as of the date of measurement; (ii) following the first
anniversary of the date hereof, the number of outstanding shares of our common
stock which were first issued to the Ecolochem Selling Stockholders in
connection with the consummation of the acquisition of Ecolochem, Inc. and its
affiliated companies (and any securities issued or distributed in respect of
such shares by way of conversion, dividend, stock split or other distribution,
merger, consolidation, exchange, recapitalization or reclassification) and are
still held by the former owners of the Ecolochem Group and their permitted
assigns equal less than 1% of our then outstanding shares of our common stock,
or (iii) no Ecolochem Selling Stockholder or its permitted assigns is an
"affiliate" of ours as such term is defined in Rule 144 of the Securities Act of
1933, as amended and all shares of our common stock first issued to the selling
stockholders in connection with the consummation of the acquisition of
Ecolochem, Inc. and its affiliated companies (and any securities issued or
distributed in respect of such shares by way of conversion, dividend, stock
split or other distribution, merger, consolidation, exchange recapitalization or
reclassification) may be sold in a single transaction under Rule 144(k) of the
Securities Act of 1933, as amended.
Based on representations by the selling stockholders, to the best of
our knowledge, none of the owners of the Ecolochem Group had a material
relationship with us or any of our affiliates within the three-year period
ending on the date of this prospectus.
PLAN OF DISTRIBUTION
The shares of our common stock covered by this prospectus may be
offered and sold from time to time by the selling stockholders. The term
"selling stockholders" includes pledgees, donees, transferees, designees, or
other successors-in-interest selling shares received after the date of this
prospectus from a selling stockholder as a gift, pledge, distribution of trust
proceeds or other non-sale related transfer provided that any such pledgee,
donee, transferee, designee or other successor-in-interest is either (i) another
selling stockholder, (ii) the spouse, child, grandchild, aunt, uncle, niece or
nephew of any selling stockholder, (iii) an heir, executor, administrator,
testamentary trustee, legatee or beneficiary of any selling stockholder or (iv)
- 13 -
a trust, the beneficiaries of which, or a corporation or partnership, the
stockholders or general and limited partners of which, include only one or more
of the persons specified in clauses (i), (ii) and (iii). The selling
stockholders will act independently of us in making decisions with respect to
the timing, manner and size of each sale. Such sales may be made on one more
exchanges or in the over-the-counter market or otherwise, at prices and under
terms then prevailing or at prices related to the then-current market price or
in negotiated transactions. The selling stockholders may sell their shares by
one or more of, or a combination of, the following methods:
o purchases by a broker-dealer as principal and resale by such broker-dealer for
it own account pursuant to this prospectus;
o ordinary brokerage transactions and transactions in which the broker solicits
purchasers
o block trades in which the broker-dealer so engaged will attempt to sell the
shares as agent but may position and resell a portion of the block as
principal to facilitate the transaction;
o in privately negotiated transactions;
o in options transactions; and
o through other means.
In addition, any shares that qualify for sale pursuant to Rule 144 of
the Securities Act of 1933, as amended, may be sold under Rule 144 rather than
pursuant to this prospectus. No selling stockholder has entered into any
agreement with a prospective underwriter and there is no assurance that any such
agreement will be entered into.
To the extent required, this prospectus may be amended or supplemented
from time to time to describe a specific plan of distribution. In connection
with distributions of the shares or otherwise, the selling stockholders may
enter into hedging transactions with broker-dealers or other financial
institutions. In connection with such transactions, broker-dealers or other
financial institutions may engage in short sales of the common stock in the
course of hedging the positions they assume with selling stockholders. The
selling stockholders may also sell the common stock short and redeliver the
shares to close out such short positions. The selling stockholders may also
enter into option or other transactions with broker-dealers or other financial
institutions which require the delivery to such broker-dealer or other financial
institution of shares offered by this prospectus, which shares such
broker-dealer or other financial institution may resell pursuant to this
prospectus (as supplemented or amended to reflect such transaction). The selling
stockholders may also pledge shares to a broker-dealer or other financial
institution, and, upon a default, such broker-dealer or other financial
institution, may effect sales of the pledged shares pursuant to this prospectus
(as supplemented or amended to reflect such transaction).
In effecting sales, broker-dealers or agents engaged by the selling
stockholders may arrange for other broker-dealers to participate. Broker-dealers
or agents may receive commissions, discounts or concessions from the selling
stockholders in amounts to be negotiated immediately prior to the sale.
In offering the shares covered by this prospectus, the selling
stockholders and any broker-dealers who execute sales for the selling
stockholders may be deemed to be "underwriters" within the meaning of the
Securities Act of 1933, as amended, in connection with such sales. Any profits
realized by the selling stockholders and compensation of any broker-dealer may
be deemed to be underwriting discounts and commissions.
In order to comply with the securities laws of certain jurisdictions,
the shares offered by this prospectus may need to be offered or sold in such
jurisdictions only through registered or licensed brokers or dealers.
- 14 -
Under applicable rules and regulations under the Securities Exchange
Act of 1934, any person engaged in a distribution of the shares of common stock
covered by this prospectus may be limited in their ability to engage in market
activities with respect to such shares. The selling stockholders, for example,
will be subject to applicable provisions of the Securities Exchange Act of 1934
and the rules and regulations under it, including, without limitation Regulation
M, which provisions may restrict certain activities of the selling stockholders
and limit the timing of purchases and sales of any shares of common stock by the
selling stockholders. Furthermore, under Regulation M, persons engaged in a
distribution of securities are prohibited from simultaneously engaging in market
making and certain other activities with respect to such securities for a
specified period of time prior to the commencement of such distributions,
subject to specified exceptions or exemptions. The foregoing may affect the
marketability of the shares offered by this prospectus.
We have agreed to pay the fees and expenses incurred in effecting the
registration of the shares covered by this prospectus, including, without
limitation, all registration and filing fees, New York Stock Exchange listing
fees, and fees and expenses of our counsel, one counsel to the Ecolochem Selling
Stockholders and our accountants. The selling stockholders will pay any
underwriting discounts and commissions and expenses incurred by the selling
stockholders in disposing of the shares. We will not receive any of the proceeds
from the sale of our common stock by the selling stockholders.
We have agreed to indemnify the selling stockholders against certain
liabilities, including certain liabilities under the Securities Act of 1933, as
amended.
We have agreed to use our commercially reasonable efforts to keep the
registration statement effective, solely with respect to the shares held by the
Ecolochem Selling Stockholders, for the period from effectiveness of the
registration statement of which this prospectus forms a part until the first
date on which (i) the Ecolochem Selling Stockholders cease to hold in the
aggregate a number of shares of common stock equal to the lesser of (a) at least
5% of the number of outstanding shares of our common stock as of the close of
business on the day immediately preceding the date upon which we consummate the
acquisition of Ecolochem, Inc. and its affiliated companies and (b) at least 5%
of the number of outstanding shares of our common stock at the date of
measurement; (ii) following the first anniversary of the date hereof, the number
of outstanding shares of our common stock which were first issued to the
Ecolochem Selling Stockholders in connection with the consummation of the
acquisition of Ecolochem, Inc. and its affiliated companies (and any securities
issued or distributed in respect of such shares by way of conversion, dividend,
stock split or other distribution, merger, consolidation, exchange,
recapitalization or reclassification) and are still held by the Ecolochem
Selling Stockholders and their permitted assigns equal less than 1% of our then
outstanding shares of our common stock, or (iii) no Ecolochem Selling
Stockholder or its permitted assigns is an "affiliate" of ours as such term is
defined in Rule 144 of the Securities Act of 1933, as amended, and all shares of
our common stock first issued to the Ecolochem Selling Stockholders in
connection with the consummation of the acquisition of Ecolochem, Inc. and its
affiliated companies (and any securities issued or distributed in respect of
such shares by way of conversion, dividend, stock split or other distribution,
merger, consolidation, exchange recapitalization or reclassification) may be
sold in a single transaction under Rule 144(k) of the Securities Act of 1933, as
amended. We may suspend the rights of the Ecolochem Selling Stockholders to
resell shares under this prospectus under certain limited circumstances.
Equiserve Trust Company, N.A., 150 Royall Street, Canton, MA 02021, is the
transfer agent for the shares of our common stock.
LEGAL MATTERS
The validity of the shares of our common stock offered hereby will be
passed upon for us by Stephen Korn, Vice President and General Counsel of
Ionics. Mr. Korn beneficially owns 128,816 shares of our common stock, which
number includes 128,829 shares subject to options, as to which Mr. Korn has the
- 15 -
right to acquire beneficial ownership, and 1,606 shares (as of February 6, 2004)
in our Section 401(k) Plan for the account of Mr. Korn.
EXPERTS
The consolidated financial statements as of December 31, 2002 and 2001
and for each of the three years in the period ended December 31, 2002
incorporated in this Prospectus by reference to Ionics, Incorporated's Current
Report on Form 8-K dated December 24, 2003, have been so incorporated in
reliance on the reports of PricewaterhouseCoopers LLP, independent accountants,
given on the authority of said firm as experts in auditing and accounting.
The combined financial statements of the Ecolochem Group incorporated
in this prospectus by reference to our Proxy Statement dated January 9, 2004,
have been so incorporated in reliance upon the report of KPMG LLP, independent
accountants given on the authority of said firm as experts in auditing and
accounting.
WHERE YOU CAN FIND MORE INFORMATION
We file annual, quarterly and current reports, proxy statements and
other information with the Securities and Exchange Commission. You may read and
copy any document we file with the Securities and Exchange Commission at the
Securities and Exchange Commission's public reference room at 450 Fifth Street,
N.W., Washington, D.C. 20549. You should call the Securities and Exchange
Commission at 1-800-SEC-0330 for further information on operation of the public
reference room. Our Securities and Exchange Commission filings are also
available to the public from the Securities and Exchange Commission's Internet
site at http://www.sec.gov and from our Internet site at http://www.ionics.com.
In addition, these materials may be read at the offices of the New York Stock
Exchange, 20 Broad Street, New York, New York 10005.
This prospectus is part of a registration statement that we filed with
the Securities and Exchange Commission. The registration statement contains more
information than this prospectus regarding us and our common stock, including
certain exhibits and schedules. You can obtain a copy of the registration
statement from the Securities and Exchange Commission at the address listed
above or from the Securities and Exchange Commission's Internet site.
INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE
The Securities and Exchange Commission allows us to "incorporate by
reference" the information we file with them, which means that we can disclose
important information to you by referring you to those documents. The
information incorporated by reference is considered to be part of this
prospectus. We incorporate by reference the following documents:
(a) Our Annual Report on Form 10-K for the fiscal year ended December
31, 2002, as amended, as amended by Form 10-K/A filed with the SEC on April
1, 2003, Form 11-K filed with the SEC on June 26, 2003 and Form 10-K/A filed
with the SEC on October 2, 2003;
(b) Our Proxy Statement filed with the SEC on January 9, 2004 pursuant
to the Securities Exchange Act of 1934, as amended, which contains the
audited combined financial statements for the Ecolochem Group as of
September 30, 2003 and 2002, and for each of the years in the three-year
period ended September 30, 2003 and the unaudited pro forma combined
condensed balance sheet as of September 30, 2003 and the unaudited pro forma
combined condensed statements of operations for the nine months ended
September 30, 2003 and the fiscal year ended December 31, 2002, and the
additional proxy solicitation materials filed with the SEC on January 15,
2004 pursuant to the Securities Exchange Act of 1934, as amended;
- 16 -
(c) Our Quarterly Reports on Form 10-Q for the fiscal quarters ended
March 31, 2003 (as amended by Form 10-Q/A filed with the SEC on October 2,
2003), June 30, 2003 and September 30, 2003;
(d) Our Current Reports on Form 8-K filed on May 6, 2003, August 1,
2003, October 7, 2003, November 4, 2003, November 19, 2003, November 26,
2003 and December 24, 2003 (which contains our audited financial statements
as of December 31, 2002 and 2001 and for each of the years in the three-year
period ended December 31, 2002); and
(e) The section entitled "Description of Registrant's Securities to be
Registered" contained in our Registration Statement on Form 8-A, filed with
the SEC on September 27, 1990 pursuant to Section 12(g) of the Securities
Exchange Act of 1934, as amended..
All documents we file with the Securities and Exchange Commission under
Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as
amended, subsequent to the date of this prospectus and prior to the earlier of
the sale of all the shares of common stock covered by this prospectus and the
termination of the offering of the shares of common stock covered by this
prospectus shall be deemed incorporated by reference into this prospectus and to
be a part hereof from the date of filing of such documents.
Any statement contained in a document incorporated or deemed to be
incorporated by reference herein shall be deemed to be modified or superseded
for purpose of this prospectus to the extent that a statement contained herein
or in any other subsequently filed document which also is or is deemed to be
incorporated by reference herein modifies or supersedes such statement. Any such
statement so modified or superseded shall not be deemed, except as so modified
or superseded, to constitute a part of this prospectus.
We will provide to each person, including any beneficial owner, to whom
a prospectus is delivered, a copy of any or all of the information that has been
incorporated by reference in this prospectus (including any exhibits to such
documents that are specifically incorporated by reference in that information,
but excluding other exhibits to such documents) but not delivered with this
prospectus. You may request a copy of these documents at no cost, by writing or
telephoning Stephen Korn, Clerk, Ionics, Incorporated, 65 Grove Street,
Watertown, MA 02472-2882, telephone (617) 673-4450.
This prospectus is part of a registration statement we filed with the
Securities and Exchange Commission. You should rely only on the information
incorporated by reference, provided in this prospectus, or any supplement that
we have referred you to. We have authorized no one to provide you with different
information. You should not assume that the information in this prospectus or
any supplement is accurate as of any date other than the date on the front of
those documents. However, you should realize that the affairs of Ionics may have
changed since the date of this prospectus. This prospectus will not reflect such
changes. You should not consider this prospectus to be an offer or solicitation
relating to the securities in any jurisdiction in which such an offer or
solicitation relating to the securities is not authorized. Furthermore, you
should not consider this prospectus to be an offer or solicitation relating to
the securities if the person making the offer or solicitation is not qualified
to do so, or if it is unlawful for you to receive such an offer or solicitation.
- 17 -
PART II
INFORMATION NOT REQUIRED IN PROSPECTUS
Item 14. Other Expenses of Issuance and Distribution.
The following table sets forth an estimate (other than with respect to
the Securities and Exchange Commission registration fee) of the expenses
expected to be incurred in connection with the issuance and distribution of the
securities being registered, all of which will be borne by Ionics, Incorporated
(except any underwriting discounts and commissions incurred by the selling
stockholders in disposing the shares):
Registration Fee -- Securities and Exchange Commission............$ 11,953.62
Accounting Fees and Expenses......................................$ 5,000.00
Legal Fees and Expenses...........................................$ 20,000.00
Miscellaneous ....................................................$ 5,000.00
--------------
TOTAL....................................................$ 41,953.62
==============
Item 15. Indemnification of Directors and Officers.
Ionics is permitted by the Massachusetts Business Corporation Law and
required by its By-laws to indemnify any director or officer or former director
or officer against all expenses and liabilities reasonably incurred by him or
her in connection with any legal action in which such person is involved by
reason of his position with Ionics unless he or she shall have been finally
adjudicated in any action, suit or proceeding not to have acted in good faith in
the reasonable belief that his action was in the best interests of Ionics. Such
indemnification shall include payment by Ionics of expenses incurred in
defending a civil or criminal action or proceeding in advance of the final
disposition of such action or defending a civil or criminal action or
proceeding, upon Ionics' receipt of the undertaking of the person indemnified to
repay such payment if such person shall be adjudicated not entitled to such
indemnification.
Directors and officers of Ionics are also insured up to an aggregate of
$15,000,000 under a Directors' and Officers' Liability and Company Reimbursement
Policy, and up to an additional $5,000,000 under a Directors' and Officers'
Liability Policy.
The Restated Articles of Organization of Ionics includes a provision
limiting the personal liability of directors of Ionics to its stockholders for
monetary damages for breaches of their fiduciary duty to the extent permitted by
the Massachusetts Business Corporation Law...
Item 16. Exhibits.
The following exhibits, required by Item 601 of Regulation S-K, are
filed as a part of this Registration Statement. Exhibit numbers, where
applicable, in the left column correspond to those of Item 601 of Regulation
S-K.
Exhibit No. Item and Reference
----------- ------------------
2.1 Purchase Agreement dated as of November 18, 2003
between the individuals and entities listed on Exhibit
A thereto and Ionics Incorporated (filed as Exhibit 2.1
to the Current Report on Form 8-K of Ionics dated
November 26, 2003 and incorporated herein by
reference).
- II-1 -
4.1 Form of Stockholders Agreement among Ionics,
Incorporated and the Individuals and Entities listed on
Exhibit A thereto (filed as Annex B to the Proxy
Statement on Schedule 14A of Ionics filed on January 9,
2004 and incorporated herein by reference).
4.2 Renewed Rights Agreement, dated as of August 19, 1997
between Registrant and BankBoston N.A. as Rights Agent
(filed as Exhibit 1 to the Current Report on Form 8-K
of Ionics dated August 27, 1997 and incorporated herein
by reference).
4.3 Amendment No. 1 dated as of November 17, 2003, to the Renewed
Rights Agreement dated August 19, 1997 between Ionics,
Incorporated and EquiServe Trust Company as Rights Agent (and
successor in interest to BankBoston N.A.)(filed as Exhibit 4.1 to
the Current Report on Form 8-K of Ionics dated November 26, 2003
and incorporated herein by reference).
4.4 Form of Common Stock Certificate (filed as Exhibit 4.2
to Annual Report on Form 10-K of Ionics for year ended
December 31, 1997 and incorporated herein by
reference).
4.5 Option Agreement dated as of March 21, 1995 by and between Ionics,
Incorporated and Ruthal Limited (filed herewith).
4.6 Option Agreement dated as of June 1, 1995 by and between Ionics,
Incorporated and Ruthal Limited (filed herewith).
5 Opinion of Stephen Korn, Esquire (filed herewith).
23.1 Consent of PricewaterhouseCoopers LLP (filed herewith).
23.2 Consent of KPMG LLP (filed herewith)
23.3 Consent of Stephen Korn, Esquire (included in Exhibit 5).
24 Power of Attorney (included on signature pages).
Item 17. Undertakings.
The undersigned registrant hereby undertakes:
(1) To file, during any period in which offers or sales are being made,
a post-effective amendment to this registration statement:
(i) To include any prospectus required by Section 10(a)(3) of the
Securities Act of 1933, as amended;
(ii) To reflect in the prospectus any facts or events arising
after the effective date of the registration statement (or the most
recent post-effective amendment thereof) which, individually or in the
aggregate, represents a fundamental change in the information set
forth in the registration statement. Notwithstanding the foregoing,
any increase or decrease in volume of securities offered (if the total
dollar value of securities offered would not exceed that which was
registered) and any deviation from the low or high and of the
estimated maximum offering range may be reflected in the form of
prospectus filed with the Securities and Exchange Commission pursuant
to Rule 424(b) if, in the aggregate, the changes in volume and price
represent no more than 20 percent change in the maximum aggregate
offering price set forth in the "Calculation of Registration Fee"
table in the effective registration statement; and
- II-2 -
(iii) To include any material information with respect to the
plan of distribution not previously disclosed in the registration statement or
any material change to such information in the registration statement;
provided, however, that paragraphs (1)(i) and 1(ii) do not apply if the
information required to be included in a post-effective amendment by those
paragraphs is contained in periodic reports filed with or furnished to the
Commission by the registrant pursuant to Section 13 or Section 15(d) of the
Securities Exchange Act of 1934, as amended, that are incorporated by reference
in the registration statement.
(2) That, for the purpose of determining any liability under the
Securities Act of 1933, as amended, each such post-effective amendment shall be
deemed to be a new registration statement relating to the securities offered
therein, and the offering of such securities at that time shall be deemed to be
the initial bona fide offering thereof.
(3) To remove from registration by means of a post-effective amendment
any of the securities being registered which remain unsold at the termination of
the offering.
The undersigned registrant hereby undertakes that, for purposes of
determining any liability under the Securities Act of 1933, as amended, each
filing of the registrant's annual report pursuant to Section 13(a) or 15(d) of
the Securities Exchange Act of 1934, as amended (and, where applicable, each
filing of an employee benefit plan's annual report pursuant to Section 15(d) of
the Securities Exchange Act of 1934, as amended) that is incorporated by
reference in the registration statement shall be deemed to be a new registration
statement relating to the securities offered therein, and the offering of such
securities at that time shall be deemed to be the initial bona fide offering
thereof.
Insofar as indemnification for liabilities arising under the Securities
Act of 1933, as amended, may be permitted to directors, officers and controlling
persons of the registrant pursuant to provisions described in Item 15 above, or
otherwise, the registrant has been advised that in the opinion of the Securities
and Exchange Commission such indemnification is against public policy as
expressed in the Securities Act of 1933, as amended, and is, therefore,
unenforceable. In the event that a claim for indemnification against such
liabilities (other than the payment by the registrant of expenses incurred or
paid by a director, officer or controlling person of the registrant in the
successful defense of any action, suit or proceeding) is asserted by such
director, officer or controlling person in connection with the securities being
registered, the registrant will, unless in the opinion of its counsel the matter
has been settled by controlling precedent, submit to a court of appropriate
jurisdiction the question whether such indemnification by it is against public
policy as expressed in the Securities Act of 1933, as amended, and will be
governed by the final adjudication of such issue.
- II-3 -
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the
registrant certifies that it has reasonable grounds to believe that it meets all
of the requirements for filing on Form S-3 and have duly caused this
registration statement to be signed on its behalf by the undersigned, thereunto
duly authorized in the City of Watertown, Commonwealth of Massachusetts on
February 11, 2004.
Ionics, Incorporated
By:/s/ Douglas R. Brown
--------------------
Douglas R. Brown
President and Chief Executive Officer
Pursuant to the requirements of the Securities Act of 1933, this registration
statement has been signed below by the following persons on behalf of the
Registrant and in the capacities and on the dates indicated.
Name Capacity Date
---- -------- ----
/s/ Douglas R. Brown President and Chief Executive Officer February 11, 2004
-----------------------------------
Douglas R. Brown (principal executive officer) and Director
/s/ Daniel M. Kuzmak Vice President, Finance and Chief Financial February 11, 2004
-----------------------------------
Daniel M. Kuzmak Officer (principal financial officer)
/s/ Anthony Di Paola Vice President and Corporate Controller February 11, 2004
-----------------------------------
Anthony Di Paola (principal accounting officer)
/s/ Stephen L. Brown* Director February 11, 2004
-----------------------------------
Stephen L. Brown
/s/ Arthur L. Goldstein* Chairman of the Board and Director February 11, 2004
-----------------------------------
Arthur L. Goldstein
Director
-----------------------------------
Kathleen F. Feldstein
/s/ William K. Reilly* Director February 11, 2004
-----------------------------------
William K. Reilly
/s/ John J. Shields* Director February 11, 2004
-----------------------------------
John J. Shields
/s/ Daniel I. C. Wang* Director February 11, 2004
-----------------------------------
Daniel I. C. Wang
/s/ Mark S. Wrighton* Director February 11, 2004
-----------------------------------
Mark S. Wrighton
/s/ Allen S. Wyett* Director February 11, 2004
-----------------------------------
Allen S. Wyett
*Signed pursuant to a Power of Attorney by Stephen Korn, such Power of Attorney
being granted pursuant to the original filing of this Registration Statement on
Form S-3 as filed on January 20, 2004.
/s/Stephen Korn
Stephen Korn
INDEX TO EXHIBITS
Exhibit No. Item and Reference
----------- ------------------
2.1 Purchase Agreement dated as of November 18, 2003
between the individuals and entities listed on Exhibit
A thereto and Ionics Incorporated (filed as Exhibit 2.1
to the Current Report on Form 8-K of Ionics dated
November 26, 2003 and incorporated herein by
reference).
4.1 Form of Stockholders Agreement among Ionics,
Incorporated and the Individuals and Entities listed on
Exhibit A thereto (filed as Annex B to the Proxy
Statement on Schedule 14A of Ionics filed on January 9,
2004 and incorporated herein by reference).
4.2 Renewed Rights Agreement, dated as of August 19, 1997
between Registrant and BankBoston N.A. as Rights Agent
(filed as Exhibit 1 to the Current Report on Form 8-K
of Ionics dated August 27, 1997 and incorporated herein
by reference).
4.3 Amendment No. 1 dated as of November 17, 2003, to the
Renewed Rights Agreement dated August 19, 1997 between
Ionics, Incorporated and EquiServe Trust Company as
Rights Agent (and successor in interest to BankBoston
N.A.)(filed as Exhibit 4.1 to the Current Report on
Form 8-K of Ionics dated November 26, 2003 and
incorporated herein by reference).
4.4 Form of Common Stock Certificate (filed as Exhibit 4.2
to Annual Report on Form 10-K of Ionics for year ended
December 31, 1997 and incorporated herein by
reference).
4.5 Option Agreement dated as of March 21, 1995 by and
between Ionics, Incorporated and Ruthal Limited (filed
herewith).
4.6 Option Agreement dated as of June 1, 1995 by and
between Ionics, Incorporated and Ruthal Limited (filed
herewith).
5 Opinion of Stephen Korn, Esquire (filed herewith).
23.1 Consent of PricewaterhouseCoopers LLP (filed herewith).
23.2 Consent of KPMG LLP (filed herewith)
23.3 Consent of Stephen Korn, Esquire (included in
Exhibit 5).
24 Power of Attorney (included on signature pages).
Exhibit 4.5
OPTION AGREEMENT
AGREEMENT made as of the 21st day of March, 1995, by and between IONICS,
INCORPORATED, a Massachusetts corporation ("IONICS"); AND RUTHAL LIMITED, a
corporation organized under the laws of the Isle of Man (the "Option Holder").
WITNESSETH:
WHEREAS, the Option Holder desires to acquire an option to purchase
common stock, par value $1 per share ("Common Stock") of IONICS; and
WHEREAS, IONICS is willing to issue such an option to the Option Holder
for good and valuable consideration;
NOW THEREFORE, in consideration of the premises, the mutual agreements
hereinafter set forth and the receipt by IONICS of good and valuable
consideration, the parties hereby agree as follows:
1. Grant of Option
Subject to the terms and conditions hereinafter set forth, IONICS hereby
grants to the Option Holder an option to purchase (the "Option") from IONICS,
during the period hereinafter specified, a total of 5,000 shares of Common
Stock at a price of $27.50 per share.
2. Term and Exercisability of Option
(a) The Option shall be exercisable in installments as follows: to the
extent of 500 shares on and after the first anniversary of the date hereof;
and to the extent of an additional 500 shares on and after each succeeding
anniversary of the date hereof, so that this Option shall become fully
exercisable on the tenth anniversary of the date hereof, subject to Section
2(b) hereof. Such installments shall be cumulative, and this Option shall be
exercisable at any time as to all, or from time to time as to part, of the
shares then eligible for exercise. At no time shall the Option be exercised
for fewer than 500 shares. This Option and all of the Option Holder's rights
hereunder shall terminate on the close of business on the thirtieth (30th) day
following the tenth anniversary of the date hereof, subject to Section 2(b)
hereof.
(b) In the event that the Option Holder does not cause consulting
services to be rendered to IONICS in any year or years during the term hereof
which are deemed satisfactory by IONICS, then IONICS will have the right to
delay by one year the exercisability of the 500 share block that would have
become exercisable in such year. In the event the exercisability of one or
more installments is so delayed, the exercise price of the delayed
installment(s) shall be adjusted as follows: for such installment, if any, of
this Option which becomes exercisable on the eleventh anniversary of the date
hereof, the exercise price shall be the average last sales price, as reflected
in the records of the New York Stock Exchange (Average Sales Price), in 1996;
for such installment, if any, of this Option which becomes exercisable on the
twelfth anniversary of the date hereof, the exercise price shall be the
Average Sales Price in 1997, and for each additional installment of this
Option granted hereunder with delayed exercisability, the exercise price shall
be the next successive year's Average Sales Price. In the event of the delay
in exercisability of one or more installments of this Option pursuant to this
Section 2(b), this Option, and all of the Option Holder's rights hereunder,
shall terminate on the close of business on the thirtieth (30th) day following
such anniversary of the date hereof as the Option granted hereunder first
becomes fully exercisable.
3. Method of Exercise
The Option shall be exercised, once if for all the shares or from time
to time as to part, by the Option Holder.
4. Assignability of Option Rights
The Options may be exercised only by the Option Holder and shall not be
encumbered, nor otherwise be assignable or transferable. In the event any
attempt shall be made by an Option Holder to assign or transfer the Option, or
any of its rights hereunder, whether voluntarily or involuntarily, by
operation of law or otherwise, the Option shall immediately terminate and be
of no further force or effect, and no interest or right hereunder shall vest
in any other person.
5. Notice of Exercise
To the extent then exercisable, this Option may be exercised from time to
time by written notice to IONICS substantially in the form attached hereto as
Exhibit 1. As soon as practicable after its receipt of such notice, IONICS shall
deliver or cause to be delivered to the Option Holder, stock certificates
representing the number of shares to be issued upon such exercise, against
payment of the option price in full for the number of shares to be delivered, by
means of payment acceptable to IONICS; provided, however, that the time of such
delivery may be postponed by IONICS for such period as may be required for it
with reasonable diligence to comply with any applicable law.
6. Compliance with United States Securities Laws
(a) The Option Holder hereby represents that it will be acquiring the
Common Stock pursuant to an exemption from registration for public sale under
federal and state securities laws in the United States or any other jurisdiction
on the grounds that the acquisition by the Option Holder of such Common Stock as
hereby contemplated is exempt from such registration because it does not involve
a public offering, or on the basis of other applicable exemption provisions of
said laws. The Option Holder further represents that it will be acquiring the
Common Stock for investment not with a view to its sale of distribution, and as
a condition to being issued the Common Stock, it hereby covenants and agrees
with IONICS that no transfer, sale, exchange, assignment, pledge or encumbrance
of the Common Stock or any portion thereof, nor any commitment to take such
action, shall be made, whether voluntarily, involuntarily, or by operation of
law, by bequest or otherwise, without prior written notice to IONICS, and
compliance with this Agreement and all applicable securities laws. The Option
Holder further covenants that it will comply with U.S. laws and any applicable
stock exchange regulations relating to its acquisition of Common Stock pursuant
to its exercise of the Option.
(b) If any time during the term of this Option Agreement, IONICS shall
determine to register any of its Common Stock under the Securities Act of 1993,
as amended (the "Act"), other than pursuant to Form S-8 or a similar form with
respect to employee benefit plans, it will give to the option Holder prompt
written notice thereof and afford an opportunity for the Option Holder to
include any Common Stock it acquires upon the exercise of this Option in such
registration without expense to the Option Holder, provided that: (1) such
request is made in writing to IONICS within ten (10) business days after being
given said notice; (2) the inclusion is permissible under the Act and rules and
regulations thereunder; (3) the price for which said shares will be offered
shall not be less than the price for which IONICS offers Shares under the
registration; (4) such shares of Common Stock are not at the time of such
proposed offering transferable pursuant to Rule 144 under the Act or a similar
exemption from registration; and (5) if the proposed offering by IONICS is to be
underwritten, the managing underwriter shall advise IONICS in writing that the
inclusion of said shares in the registered offering would not be materially
detrimental to the prospects for successfully effecting the offering proposed by
IONICS alone (in connection with this proviso, IONICS agrees that the Common
Stock of the Option Holder for purposes of such registration will be treated
pari passu with any other restricted stock for which "piggyback" registration
may be requested from time to time); provided that the Option Holder agrees
that, in connection with any such registration of all or any part of the shares
of Common Stock, it shall furnish to IONICS accurately and in writing with all
information concerning the Option Holder and its offering reasonably required
for IONICS properly to prepare and file such registration statement in
accordance with the provisions of the Act.
7. Rights as Stockholder
No person shall have any rights as a stockholder with respect to any shares of
Common Stock covered by this Option until the date of issuance of a stock
certificate to such person for such shares. No adjustment shall be made for
dividends or other rights for which the record date is prior to the date of
issuance of such stock certificate.
8. Changes in Capital Structure
The existence of this Option shall not affect in any way the rights or power of
IONICS to make or authorize any or all adjustments, recapitalizations,
reorganizations or other changes in the capital structure or business of IONICS,
or any merger or consolidation of IONICS, or any issue of bonds, debentures, or
prior preference stocks ahead of or affecting the Common Stock of IONICS or the
rights thereof, or any other corporate act or proceeding. In the event that the
outstanding shares of Common Stock of IONICS are hereafter increased or
decreased or changed into or exchanged for a different number or kind of shares
or other securities of IONICS, by reason of any reorganization, merger,
consolidation recapitalization, reclassification, stock split-up, combination of
shares or dividend payable in capital stock, the Board of Directors of IONICS
shall make appropriate adjustment in the number of shares as to which this
Option, or the portion hereof then unexercised shall be exercisable, and in the
option price (provided that in no event shall the option price be less than the
par value of such shares) to the end that the Option Holder's proportionate
interest shall be maintained as before the occurrence of such event.
9. No Fractional Shares
If the number of shares of Common Stock purchasable upon the exercise of the
Option is adjusted pursuant to paragraph 8, IONICS shall not in any event be
required to issue fractions of shares upon the exercise of the Option or to
distribute stock certificates which evidence fractional shares, but shall make
an adjustment therefore in cash on the basis of the last reported sales price on
the exchange on which the Common Stock is then traded on the trading day
immediately prior to the date of exercise. If the Common Stock is not being
traded at the time of exercise, then the cash adjustment shall be made on the
basis of the then market value of the Common Stock as shall be reasonably
determined by the Board of Directors of IONICS.
10. Payment of Taxes
Any taxes which may be incurred in connection with the initial issuance of
shares of Common Stock upon the exercise of the Option, based upon the income of
the Option Holder or otherwise resulting from the tax status of the Option
Holder or which may be incurred in connection with any transfer of certificates
in a name other than an Option Holder, will be paid by the Option Holder.
11. Additional Obligations of Option Holder
The Option Holder agrees that in the event it exercises the Option and acquires
some or all of the shares of Common Stock purchasable hereunder (the "Shares"):
(a) If the option Holder desires to dispose of all or any of the Shares, it
will transmit to IONICS a written notice (the "Written Notice") setting
forth the number of Shares proposed to be disposed of. Upon receipt of the
Written Notice, IONICS will have an option for five business days, unless
the Option Holder has received a bona fide offer to purchase the shares and
the time period set forth in the bona fide offer is shorter, in which event
the shorter period shall apply (the "Period"), excluding the day upon which
the Written Notice is received, to issue a written commitment to purchase
the number of Shares specified in the Written Notice at a purchase price
that shall be the higher of (i) the "Market Price" (the average of the
closing prices on the New York Stock Exchange, or such other exchange upon
which the Shares may then be traded, for the two trading days immediately
preceding the date of the Written Notice, or (ii) in the event the Option
Holder has received a good faith bona fide offer to purchase the Shares,
the price per share contained in such offer and upon the payment terms
stipulated in such offer; provided, however, that if such offer price is
more than ten percent (10%) greater than the Market Price, the purchase
price shall be the mean thereof; and provided further that the Option
Holder shall provide IONICS with such information as IONICS may reasonably
request to confirm the bona fides of the offer.
If IONICS does not notify the Option Holder of its intention to purchase
the specified number of Shares on or before the close of business on the
last day of the Period, then the Option Holder shall have 30 days from
the end of the Period to consummate the disposition of the specified
number of Shares, which the Option Holder may not sell at less than the
Market Price.
Following 30 days from the end of the Period, any Shares not so disposed
of will continue to be subject to the terms and conditions of this
Agreement to the same extent as if the disposition had not been
proposed.
If IONICS notifies the Option Holder within the five business days that
is intends to purchase the specified number of Shares, then IONICS will
have an additional five business days from the date of such notice to
pay for such Shares (or such longer period as may have been stipulated
in any bona fide offer which the Option Holder may have received). The
option Holder will retain record and beneficial ownership of the Shares
until the Option Holder has received payment therefore from IONICS.
IONICS' rights to purchase Common Stock under this Agreement will not be
assignable except to corporate successors of IONICS. The term "dispose"
does not include any pledge of the Shares for bona fide financing
purposes so long as the pledgee agrees that the Shares are subject to
IONICS' right of first offer prior to any disposition by the pledgee.
(b) Without IONICS' prior written consent, and other than as provided in this
Agreement, neither the Option Holder nor any of its affiliates will
acquire, offer or propose to acquire or agree to acquire, directly or
indirectly, by purchase or otherwise, such additional shares of IONICS
Common Stock or direct or indirect rights or options to acquire (through
purchase, exchange, conversion or otherwise) such stock so as to bring
total beneficial ownership by such group above 66,666 shares of IONICS
Common Stock. This restriction shall not be violated if the percentage of
the outstanding shares of Common Stock beneficially owned in the aggregate
by the Option Holder (individually or together with its affiliates) is
increased solely as a result of a recapitalization of IONICS, by a
repurchase of securities by IONICS or by any action taken by IONICS. For
the purposes of this section "affiliates" shall mean all entities
controlled by the Option Holder, or under common control with the Option
Holder.
(c) The Option Holder hereby agrees that it will provide from time to time, so
long as options for any of the Shares remain exercisable and have not been
exercised pursuant to this Agreement, its proxy to the management of
IONICS to vote any such Shares it does own at any meeting or in connection
with any unanimous consent in writing of the Stockholders of IONICS for
which proxies are solicited.
12. Notices
Any notice from IONICS or from the Option Holder shall be deemed to have
been properly given if in writing and sent by registered or certified mail,
postage prepaid, to the persons being given the notice at the following address,
unless such an address has been changed by notice given in compliance herewith.
The Corporation:
Ionics, Incorporated
65 Grove Street
Watertown MA 02172
Attn: S. Korn, Vice President and General Counsel
The Option Holder:
Ruthal Limited
________________________
________________________
13. Miscellaneous
This Agreement shall inure to the benefit of and be binding upon the respective
parties hereto, and their assigns, successors and transferees. This Agreement
shall be governed by and construed in accordance with the laws of the
Commonwealth of Massachusetts, U.S.A. This Agreement may not be altered,
modified or amended except by a further written agreement duly executed and
delivered by the respective parties hereto. This Agreement may be executed in
any number of counterparts and each of such counterparts shall for all purposes
be deemed to be an original, and all such counterparts shall together constitute
one and the same instrument.
IN WITNESS WHEREOF, IONICS, INCORPORATED, by an officer thereunto duly
authorized, and the Option Holder by an officer thereunto duly authorized, have
duly executed this Agreement as of the date first above written.
IONICS, INCORPORATED
By: /s/Arthur L. Goldstein
Arthur L. Goldstein
Chairman and
Chief Executive Officer
RUTHAL LIMITED
By: /s/L. A. Kearns
---------------------------
L. A. Kearns, Director
EXHIBIT 1
Ionics, Incorporated
65 Grove Street
Watertown, MA 02172
Gentlemen:
The undersigned hereby elects to exercise the option granted to by and to the
extent of purchase ____________ shares of the Common Stock of your Corporation
for the option price of $27.50 per share, subject to the terms and conditions of
the Option Agreement between Ruthal Limited and Ionics, Incorporated dated as of
___________, 19__.
The undersigned hereby agrees to make payment in cash of the purchase price for
said shares against delivery to the undersigned of the stock certificate
representing the shares purchased.
The undersigned hereby specifically confirms to your Corporation that the
undersigned is acquiring said shares for investment and not with a view to sale
or distribution thereof, and that said shares shall beheld subject to all of the
terms and conditions of said Agreement.
Very truly yours,
RUTHAL LIMITED
By: _______________________
Exhibit 4.6
OPTION AGREEMENT
AGREEMENT made as of the lst day of June, 1995, by and between IONICS,
INCORPORATED, a Massachusetts corporation ("IONICS"); AND RUTHAL LIMITED, a
corporation organized under the laws of the Isle of Man (the "Option Holder").
WITNESSETH:
WHEREAS, the Option Holder desires to acquire an option to purchase common
stock, par value $1 per share ("Common Stock") of IONICS; and
WHEREAS, IONICS is willing to issue such an option to the Option Holder for
good and valuable consideration;
NOW THEREFORE, in consideration of the premises, the mutual agreements
hereinafter set forth and the receipt by IONICS of good and valuable
consideration, the parties hereby agree as follows:
1. Grant of option
Subject to the terms and conditions hereinafter set forth, IONICS hereby
grants to the Option Holder an option to purchase (the "Option") from IONICS,
during the period hereinafter specified, a total of 5,000 shares of Common Stock
at a price of $27.50 per share.
2. Term and Exercisability of Option
(a) The Option shall be exercisable in installments as follows: to the
extent of 500 shares on and after the first anniversary of the date hereof; and
to the extent of an additional 500 shares on and after each succeeding
anniversary of the date hereof, so that this Option shall become fully
exercisable on the tenth anniversary of the date hereof, subject to Section 2(b)
hereof. Such installments shall be cumulative, and this Option shall be
exercisable at any time as to all, or from time to time as to part, of the
shares then eligible for exercise. At no time shall the Option be exercised for
fewer than 500 shares. This Option and all of the Option Holder's rights
hereunder shall terminate on the close of business on the thirtieth (30th) day
following the tenth anniversary of the date hereof, subject to Section 2(b)
hereof.
(b) In the event that the Option Holder does not cause consulting
services to be rendered to IONICS in any year or years during the term hereof
which are deemed satisfactory by IONICS, then IONICS will have the right to
delay by one year the exercisability of the 500 share block that would have
become exercisable in such year. In the event the exercisability of one or
more installments is so delayed, the exercise price of the delayed
installment(s) shall be adjusted as follows: for such installment, if any, of
this Option which becomes exercisable on the eleventh anniversary of the date
hereof, the exercise price shall be the average last sales price, as reflected
in the records of the New York Stock Exchange (Average Sales Price), in 1996;
for such installment, if any, of this Option which becomes exercisable on the
twelfth anniversary of the date hereof, the exercise price shall be the
Average Sales Price in 1997; and for each additional installment of this
Option granted hereunder with delayed exercisability, the exercise price shall
be the next successive year's Average Sales Price. In the event of the delay
in exercisability of one or more installments of this Option pursuant to this
Section 2(b), this Option, and all of the Option Holder's rights hereunder,
shall terminate on the close of business on the thirtieth (30th) day following
such anniversary of the date hereof as the Option granted hereunder first
becomes fully exercisable.
3. Method of Exercise
The Option shall be exercised, once if for all the shares or from time
to time as to part, by the Option Holder.
4. Assignability of Option Rights
The Options may be exercised only by the Option Holder and shall not be
encumbered, nor otherwise be assignable or transferable. In the event any
attempt shall be made by an Option Holder to assign or transfer the Option, or
any of its rights hereunder, whether voluntarily or involuntarily, by
operation of law or otherwise, the Option shall immediately terminate and be
of no further force or effect, and no interest or right hereunder shall vest
in any other person.
5. Notice of Exercise
To the extent then exercisable, this Option may be exercised from time to time
by written notice to IONICS substantially in the form attached hereto as
Exhibit 1. As soon as practicable after its receipt of such notice, IONICS
shall deliver or cause to be delivered to the Option Holder, stock
certificates representing the number of shares to be issued upon such
exercise, against payment of the option price in full for the number of shares
to be delivered, by means of payment acceptable to IONICS; provided, however,
that the time of such delivery may be postponed by IONICS for such period as
may be required for it with reasonable diligence to comply with any applicable
law.
6. Compliance with United States Securities Laws
(a) The Option Holder hereby represents that it will be acquiring the
Common Stock pursuant to an exemption from registration for public sale under
federal and state securities laws in the United States or any other
jurisdiction on the grounds that the acquisition by the Option Holder of such
Common Stock as hereby contemplated is exempt from such registration because
it does not involve a public offering, or on the basis of other applicable
exemption provisions of said laws. The Option Holder further represents that
it will be acquiring the Common Stock for investment not with a view to its
sale of distribution, and as a condition to being issued the Common Stock, it
hereby covenants and agrees with IONICS that no transfer, sale, exchange,
assignment, pledge or encumbrance of the Common Stock or any portion thereof,
nor any commitment to take such action, shall be made, whether voluntarily,
involuntarily, or by operation of law, by bequest or otherwise, without prior
written notice to IONICS, and compliance with this Agreement and all
applicable securities laws. The Option Holder further covenants that it will
comply with U.S. laws and any applicable stock exchange regulations relating
to its acquisition of Common Stock pursuant to its exercise of the option.
(b) If any time during the term of this Option Agreement, IONICS shall
determine to register any of its Common Stock under the Securities Act of
1993, as amended (the "Act"), other than pursuant to Form S-8 or a similar
form with respect to employee benefit plans, it will give to the Option Holder
prompt written notice thereof and afford an opportunity for the Option Holder
to include any Common Stock it acquires upon the exercise of this Option in
such registration without expense to the Option Holder, provided that: (1)
such request is made in writing to IONICS within ten (10) business days after
being given said notice; (2) the inclusion is permissible under the Act and
rules and regulations thereunder; (3) the price for which said shares will be
offered shall not be less than the price for which IONICS offers Shares under
the registration; (4) such shares of Common Stock are not at the time of such
proposed offering transferable pursuant to Rule 144 under the Act or a similar
exemption from registration; and (5) if the proposed offering by IONICS is to
be underwritten, the managing underwriter shall advise IONICS in writing that
the inclusion of said shares in the registered offering would not be
materially detrimental to the prospects for successfully effecting the
offering proposed by IONICS alone (in connection with this proviso, IONICS
agrees that the Common Stock of the Option Holder for purposes of such
registration will be treated pari passu with any other restricted stock for
which "piggyback" registration may be requested from time to time); provided
that the Option Holder agrees that, in connection with any such registration
of all or any part of the shares of Common Stock, it shall furnish to IONICS
accurately and in writing with all information concerning the Option Holder
and its offering reasonably required for IONICS properly to prepare and file
such registration statement in accordance with the provisions of the Act.
7. Rights as Stockholder
No person shall have any rights as a stockholder with respect to any shares of
Common Stock covered by this Option until the date of issuance of a stock
certificate to such person for such shares. No adjustment shall be made for
dividends or other rights for which the record date is prior to the date of
issuance of such stock certificate.
8. Changes in Capital Structure
The existence of this Option shall not affect in any way the rights or power of
IONICS to make or authorize any or all adjustments, recapitalizations,
reorganizations or other changes in the capital structure or business of IONICS,
or any merger or consolidation of IONICS, or any issue of bonds, debentures, or
prior preference stocks ahead of or affecting the Common Stock of IONICS or the
rights thereof, or any other corporate act or proceeding. In the event that the
outstanding shares of Common Stock of IONICS are hereafter increased or
decreased or changed into or exchanged for a different number or kind of shares
or other securities of IONICS, by reason of any reorganization, merger,
consolidation, recapitalization, reclassification, stock split-up, combination
of shares or dividend payable in capital stock, the Board of Directors of IONICS
shall make appropriate adjustment in the number of shares as to which this
Option, or the portion hereof then unexercised shall be exercisable, and in the
option price (provided that in no event shall the option price be less than the
par value of such shares) to the end that the Option Holder's proportionate
interest shall be maintained as before the occurrence of such event.
9. No Fractional Shares
If the number of shares of Common Stock purchasable upon the exercise of the
Option is adjusted pursuant to paragraph 8, IONICS shall not in any event be
required to issue fractions of shares upon the exercise of the Option or to
distribute stock certificates which evidence fractional shares, but shall make
an adjustment therefore in cash on the basis of the last reported sales price on
the exchange on which the Common Stock is then traded on the trading day
immediately prior to the date of exercise. If the Common Stock is not being
traded at the time of exercise, then the cash adjustment shall be made on the
basis of the then market value of the Common Stock as shall be reasonably
determined by the Board of Directors of IONICS.
10. Payment of Taxes
Any taxes which may be incurred in connection with the initial issuance of
shares of Common Stock upon the exercise of the Option, based upon the income of
the Option Holder or otherwise resulting from the tax status of the Option
Holder or which may be incurred in connection with any transfer of certificates
in a name other than an Option Holder, will be paid by the Option Holder.
11. Additional Obligations of Option Holder
The Option Holder agrees that in the event it exercises the Option and acquires
some or all of the shares of Common Stock purchasable hereunder (the "Shares"):
(a) If the option Holder desires to dispose of all or any of the Shares, it
will transmit to IONICS a written notice (the "Written Notice") setting
forth the number of Shares proposed to be disposed of. Upon receipt of the
Written Notice, IONICS will have an option for five business days, unless
the Option Holder has received a bona fide offer to purchase the shares and
the time period set forth in the bona fide offer is shorter, in which event
the shorter period shall apply (the "Period"), excluding the day upon which
the Written Notice is received, to issue a written commitment to purchase
the number of Shares specified in the Written Notice at a purchase price
that shall be the higher of (i) the "Market Price" (the average of the
closing prices on the New York Stock Exchange, or such other exchange upon
which the Shares may then be traded, for the two trading days immediately
preceding the date of the Written Notice, or (ii) in the event the Option
Holder has received a good faith bona fide offer to purchase the Shares,
the price per share contained in such offer and upon the payment terms
stipulated in such offer; provided, however, that if such offer price is
more than ten percent (10%) greater than the Market Price, the purchase
price shall be the mean thereof; and provided further that the Option
Holder shall provide IONICS with such information as IONICS may reasonably
request to confirm the bona fides of the offer.
If IONICS does not notify the Option Holder of its intention to purchase
the specified number of Shares on or before the close of business on the
last day of the Period, then the Option Holder shall have 30 days from
the end of the Period to consummate the disposition of the specified
number of Shares, which the Option Holder may not sell at less than the
Market Price.
Following 30 days from the end of the Period, any Shares not so disposed
of will continue to be subject to the terms and conditions of this
Agreement to the same extent as if the disposition had not been
proposed.
If IONICS notifies the Option Holder within the five business days that
is intends to purchase the specified number of Shares, then IONICS will
have an additional five business days from the date of such notice to
pay for such Shares (or such longer period as may have been stipulated
in any bona fide offer which the Option Holder may have received). The
Option Holder will retain record and beneficial ownership of the Shares
until the Option Holder has received payment therefore from IONICS.
IONICS' rights to purchase Common Stock under this Agreement will not be
assignable except to corporate successors of IONICS. The term "dispose"
does not include any pledge of the Shares for bona fide financing
purposes, so long as the pledgee agrees that the Shares are subject to
IONICS' right of first offer prior to any disposition by the pledgee.
(b) Without IONICS' prior written consent, and other than as provided in this
Agreement, neither the Option Holder nor any of its affiliates will
acquire, offer or propose to acquire or agree to acquire, directly or
indirectly, by purchase or otherwise, such additional shares of IONICS
Common Stock or direct or indirect rights or options to acquire (through
purchase, exchange, conversion or otherwise) such stock so as to bring
total beneficial ownership by such group above 66,666 shares of IONICS
Common Stock. This restriction shall not be violated if the percentage of
the outstanding shares of Common Stock beneficially owned in the aggregate
by the Option Holder (individually or together with its affiliates) is
increased solely as a result of a recapitalization of IONICS, by a
repurchase of securities by IONICS or by any action taken by IONICS. For
the purposes of this section "affiliates" shall mean all entities
controlled by the Option Holder, or under common control with the Option
Holder.
(c) The Option Holder hereby agrees that it will provide from time to time,
so long as options for any of the Shares remain exercisable and have not
been exercised pursuant to this Agreement, its proxy to the management of
IONICS to vote any such Shares it does own at any meeting or in
connection with any unanimous consent in writing of the Stockholders of
IONICS for which proxies are solicited.
12. Notices
Any notice from IONICS or from the Option Holder shall be deemed to have
been properly given if in writing and sent by registered or certified mail,
postage prepaid, to the persons being given the notice at the following address,
unless such an address has been changed by notice given in compliance herewith.
The Corporation:
Ionics, Incorporated
65 Grove Street
Watertown, MA 02172
Attn: S. Korn, Vice President and General Counsel
The Option Holder:
Ruthal Limited
--------------------------
--------------------------
13. Miscellaneous
This Agreement shall inure to the benefit of and be binding upon the
respective parties hereto, and their assigns, successors and transferees. This
Agreement shall be governed by and construed in accordance with the laws of the
Commonwealth of Massachusetts, U.S.A. This Agreement may not be altered,
modified or amended except by a further written agreement duly executed and
delivered by the respective parties hereto. This Agreement may be executed in
any number of counterparts and each of such counterparts shall for all purposes
be deemed to be an original, and all such counterparts shall together constitute
one and the same instrument.
IN WITNESS WHEREOF, IONICS, INCORPORATED, by an officer thereunto duly
authorized, and the Option Holder by an officer thereunto duly authorized, have
duly executed this Agreement as of the date first above written.
IONICS, INCORPORATED
By: /s/Arthur L. Goldstein
-------------------------------
Arthur L. Goldstein
Chairman and
Chief Executive Officer
RUTHAL LIMITED
By: /s/L. A. Kearns
----------------------------------
L. A. Kearns, Director
EXHIBIT 1
Ionics, Incorporated
65 Grove Street
Watertown, MA 02172
Gentlemen:
The undersigned hereby elects to exercise the option granted to by and to the
extent of ___________ purchase shares of the Common Stock of your Corporation
for the option price of $27.50 per share, subject to the terms and conditions of
the Option Agreement between Ruthal Limited and Ionics, Incorporated dated as of
________________, 19__.
The undersigned hereby agrees to make payment in cash of the purchase price for
said shares against delivery to the undersigned of the stock certificate
representing the shares purchased.
The undersigned hereby specifically confirms to your Corporation that the
undersigned is acquiring said shares for investment and not with a view to sale
or distribution thereof, and that said shares shall beheld subject to all of the
terms and conditions of said Agreement.
Very truly yours,
RUTHAL LIMITED
By: ______________________
EXHIBIT 5
February 11, 2004
Ionics, Incorporated
65 Grove Street
Watertown, Massachusetts 02472-2882
Re: S-3 Registration Statement
Ladies and Gentlemen:
As General Counsel to Ionics, Incorporated, a Massachusetts corporation
(the "Company"), I have represented the Company in connection with the
preparation and filing of the Company's Form S-3 Registration Statement (the
"Registration Statement"), including any amendments thereto, covering the sale
to the public of up to 4,915,660 shares of the Company's common stock (the
"Common Stock"), $1.00 par value per share (the "Shares"), which may be sold by
certain selling stockholders of the Company as set forth in the Registration
Statement.
I have reviewed the corporate proceedings taken by the Board of
Directors of the Company with respect to the authorization and issuance of the
Shares. I have also examined and relied upon originals or copies, certified or
otherwise authenticated to my satisfaction, of all corporate records, documents,
agreements or other instruments of the Company and have made all investigations
of law and have discussed with the Company's officers all questions of fact that
I have deemed necessary or appropriate.
Based upon and subject to the foregoing, I am of the opinion that the
Shares, when issued to the selling stockholders as described in the registration
statement, will be legally issued, fully paid and non-assessable.
I hereby consent to the filing of this opinion as Exhibit 5 to the
Registration Statement and to the reference to my name in the prospectus
contained in the Registration Statement under the caption "Legal Matters."
Very truly yours,
/s/ Stephen Korn
Stephen Korn
General Counsel
Exhibit 23.1
CONSENT OF INDEPENDENT ACCOUNTANTS
We hereby consent to the incorporation by reference in this
Registration Statements on Form S-3 of Ionics, Incorporated of our report dated
March 26, 2003, except for Note 6 and the second paragraph of Note 1, as to
which the date is December 23, 2003, relating to the financial statements of
Ionics, Incorporated, which appears in the Current Report on Form 8-K dated
December 24, 2003. We also consent to the references to us under the heading
"Experts" in such Registration Statement.
/s/ PricewaterhouseCoopers LLP
PricewaterhouseCoopers LLP
Boston, Massachusetts
February 11, 2004
Exhibit 23.2
CONSENT OF INDEPENDENT ACCOUNTANTS
We consent to the use of our report dated November 3, 2003 relating to the
combined financial statements of The Ecolochem Group, which report is
incorporated herein by reference, and to the reference to our firm under the
heading "experts" in the registration statement.
/s/ KPMG LLP
KPMG LLP
Norfolk, Virginia
February 10, 2004
-------------------------
TESTA, HURWITZ & THIBEAULT, LLP
-------------------------
ATTORNEYS AT LAW
125 High Street
Boston, Massachusetts 02110-2704
Office (617) 248-7000 Fax (617) 248-7100
February 11, 2004
VIA EDGAR
Securities and Exchange Commission
Division of Corporate Finance
450 Fifth Street, N.W.
Judiciary Plaza
Washington, D.C. 20549
Attn: Filing Desk
Re:Ionics, Incorporated - Registration Statement on Form S-3 (No. 333-112012)
Ladies and Gentlemen:
On behalf of Ionics, Incorporated (the "Company"), transmitted herewith
for filing with the Securities and Exchange Commission (the "Commission")
pursuant to Regulation S-T is one (1) conformed copy of Amendment No. 1 (the
"Amendment") to the Registration Statement on Form S-3 (No. 333-112012) (the
"Registration Statement") originally filed with the Commission on January 20,
2004, with exhibits, relating to the offering by certain stockholders of the
Company of an aggregate of 4,915,660 shares of common stock, par value $1.00 per
share, of the Company.
An aggregate filing fee of $11,988.75 has been paid prior to the
Company's filing of this Amendment by wire transfer to the Commission's account
at Mellon Bank. Of this amount, $11,953.62 was paid by the Company on January
20, 2004 when this Registration Statement was first filed and $35.13 is being
paid by the Company together with the filing of the Amendment. The $17,270.64
amount shown on the face of this filing would only be payable by Ionics if it
were registering all of the 4,915,660 shares as of the date hereof as it
reflects the increase in the Commission's filing fees effective after 10:00 p.m.
on January 27, 2004. This increase was not applicable to the shares originally
registered on January 20, 2004.
Pursuant to Rule 461 under the Securities Act of 1933 (the "Act"), the
Company may make a request for acceleration of the effective date of the above
referenced Registration Statement orally. As required by Rule 461, the Company
has authorized us to represent on their behalf that they are aware of their
obligations under the Act.
If you should have any questions, or require any additional
information, please contact me at (617) 248-7292, Edwin C. Pease of this office
at (617) 248-7080 or Stephen Korn, the Company's Vice President and General
Counsel, at (617) 926-2500.
Sincerely,
/s/ Mark H. Burnett
Mark H. Burnett
Enclosure